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AMYOTROPHIC LATERAL SCLEROSIS
Amyotrophic lateral sclerosis (ALS) is a progressive and fatal disease involving cell death 
of motor neurons in the cerebral cortex, brainstem and spinal cord. The disease course 
is characterized by progressive weakness and muscle atrophy, leading to disability and 
eventual death with a mean survival time of three years.2 At this moment there is no 
cure for ALS. The only drug with established effect on survival, riluzole, prolongs life with 
approximately 3-6 months.3 
In the Netherlands there are roughly 450 newly diagnosed ALS patients each year. Most 
ALS cases are sporadic, however approximately 5% of all ALS patients are familial.4, 5 
The cause of sporadic ALS is unknown, a combination of genetic susceptibility and 
environ mental factors, like smoking and pesticide exposure has been suggested.5, 6 
Clinical phenotype
The hallmark clinical picture of ALS is the combination of both upper and lower motor 
neuron (MN) involvement, with a progressive disease course. Characteristically, a patient 
with ALS presents with localized weakness, cramps and loss of function which becomes 
more severe and spreads to other body parts. Neurological examination then reveals signs 
of upper MN dysfunction, like spasticity and hyperreflexia, and lower MN dysfunction, 
like atrophy, weakness and fasciculations. Non-motor symptoms such as autonomic 
failure or sensory deficits are absent. 
However, the clinical presentation of an ALS patient is not always distinctive. There are 
marked differences in region of onset, the relative mix of upper and lower MN involvement 
and disease progression.7 At disease presentation, 25% of patients show only lower MN 
signs and 9% only upper MN signs.8 In the vast majority the initial manifestation is limited 
to the limbs, about 20% present with bulbar signs9, 3% with respiratory symptoms10 and 
about 2% have a more generalized disease onset.8 Also the rate of disease progression 
varies between ALS patients, reflected in significant differences in survival time.11 
Diagnosis 
Due to the heterogeneous disease presentation and lack of a diagnostic marker, the 
diagnosis ALS can be difficult to make. The number of misdiagnoses is high with a false-
negative rate of approximately 40%12, 13 and a false-positive diagnosis in about 8%.14 
Moreover, the median interval between symptom onset and ALS diagnosis is equal to 
one third of the life expectancy of patients.11, 15 
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A diagnosis of ALS requires verification that 1) the symptoms and signs are compatible 
with the disease, and 2) the symptoms are not explained by diseases with a similar 
presentation. The first is mainly done with clinical examination and electromyography 
(EMG). The second requirement -exclusion of so-called ALS-mimics (Box 1)- often requires 
additional diagnostic workup, such as laboratory testing, nerve conduction studies, MRI 
studies and/or muscle biopsy.
BOX 1 Examples of ALS mimics
ALS mimic
Lower MN Upper MN Lower + Upper MN 
MND SMA PLS
non-MND
radiculopathy
multifocal motor  
neuropathy
inclusion body myositis
hyperthyreoidism
neuralgic amyotrophy
benign cramp  
fasciculation syndrome
diabetic amyotrophy
chronic inflammatory 
demyelinating  
polyradiculoneuropathy
post polio syndrome
M. Kennedy
hexosaminidase A 
deficiency
hereditary spastic 
paraparesis
multiple sclerosis
HTLV-1 associated spastic 
paraparesis
M. Krabbe
adrenomyeloneuropathy
cerebrotendinous  
xanthomatosis
ischemic brain lesions + 
lower MN disease
radiculopathy +  
myelopathy
syringomyelia
syringobulbia
hyperparathyreodism
intramedullar spinal  
cord tumor 
spinal dural fistal
HIV
Lyme
syphilitic amyotrophy
paraneoplastic  
syndromes
An important aspect of the diagnostic work-up of ALS is the exclusion of other diseases that can 
present with similar symptoms and signs. These so-called ALS-mimics can be divided in diseases 
with lower motor neuron (MN) presentation, upper MN presentation or a combination of both. 
A second differentiation is based on the pathophysiology: motor neuron diseases (MND) versus 
non-MND.
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Diagnostic classification
Formal diagnostic criteria for ALS were developed in 1994 and revised in 2000.16, 17 
In these so-called “El Escorial criteria” the diagnosis ALS is expressed in levels of 
probability. A higher level of diagnostic certainty is reached if more body regions (bulbar, 
cervical, thoracic, lumbosacral) reveal combined upper and lower MN involvement (Box 2). 
The categories “possible”, “probable” and “definite” ALS are defined on clinical grounds 
alone. A special diagnostic category is “probable laboratory supported ALS”. For this 
category, EMG is used to detect subclinical lower MN involvement in order to increase 
diagnostic certainty. 
BOX 2 Revised El Escorial criteria
Upper and lower MN degeneration
AND
Progression 
AND
Absence of evidence for other disease processes
lower + upper MN  
in 1 region
OR
upper MN  
in 2 regions
OR
lower MN above 
upper MN signs
upper MN  
in ≥ 1 region
AND
EMG: denervation  
in ≥ 2 regions
lower + upper MN  
in 2 regions
lower + upper MN  
in 3 regions
Possible ALS
Probable ALS  
laboratory  
supported
Probable ALS Definite ALS
In the el Escorial criteria 4 different body regions are acknowledged: bulbar, cervical, thoracic and 
lumbosacral. Signs of upper motor neuron (MN) degeneration: spastic tone, preserved reflex in weak 
wasted limb, and/or pathological reflexes. Signs of lower MN involvement: weakness, atrophy and/or 
fasciculations. Electromyographic (EMG) lower MN involvement: a combination of chronic (large or 
unstable motor unit potentials and reduced interference pattern) and active denervation (fibrillation 
potentials or positive sharp waves). These EMG abnormalities are required in one muscle for the 
bulbar and thoracic region and in two muscles for the cervical and lumbosacral region.
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An important shortcoming of the El Escorial criteria is the low sensitivity. At diagnosis, 
only a little more than 50% of patients reach a diagnosis of probable or definite ALS and 
10% never attain a category higher than “possible ALS” before death.18 Clearly, a new 
diagnostic tool is needed to increase the sensitivity and accuracy to make a diagnosis 
of ALS. 
 
MUSCLE ULTRASONOGRAPHY
In 1942, the first paper was published describing the use of ultrasound in medicine: 
Dussik used the technique to detect brain tumors.19 From then, the scope of ultrasound 
in medicine has expanded considerably. In 1980, Heckmatt showed that ultrasonography 
can be used to detect structural muscle changes caused by neuromuscular disorders.20 
Affected muscles revealed a diminished thickness and a whiter appearance (i.e., an 
increased echo intensity).
Basis of ultrasound imaging
During ultrasound imaging, a transducer sends out pulses of high-frequency sound 
waves and also receives the echoes of these waves. The creation of an ultrasound 
image is based on computer analysis of the temporal and acoustic properties of the 
echoes. The location of a pixel in the ultrasound image is determined by the time between 
sending and receiving the ultrasound pulse. The brightness of the ultrasound image 
is determined by the amplitude of the receiving ultrasound pulse.21, 22 Reflection of the 
sound wave occurs when the ultrasound beam encounters tissue with different acoustical 
properties. For example, the acoustical properties of fibrous or fatty tissue differ from that 
of muscle tissue. 
Ultrasound in neuromuscular disorders
Ultrasound abnormaltiies have been described in several neuromuscular diseases.23-25 
In general, muscles affected by a neuromuscular disorder show a higher echo intensity, 
and diminished muscle thickness. Based on these characteristics, it is possible to 
differen tiate between neuromusculair and non-neuromuscular and between neurogenic 
disorders and myopathies in children.26-28 Similar studies have not been done in adults 
as of yet. 
Conveniently, ultrasound can also be used to detect fasciculations. Indeed, ultrasound 
has been show to detect fasciculations with higher sensitivity then needle EMG, retaining a 
comparable reliability.29 The detection of fasciculations with ultrasound has been illustrated 
in various disorders of the peripheral nervous system.29, 30 
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Quantitative muscle ultrasound scanning
Initially, both muscle thickness and echo intensity were scored visually in a semi quantitative 
way.20 Nowadays, quantitative analyse has evolved as the standard. Quantitative analysis 
of echo intensity can be achieved by computer-aided gray-scale analysis.31 Not only is 
this technique more objective, it also depends less on the experience of the examiner, 
is more sensitive to subtle changes in muscle structure and allows for comprehensive 
statistical analysis.32 Fasciculations are still scored in a semiquantitative manner. A practical 
guide for quantitative muscle ultrasound scanning is presented in Box 3.
To facilitate comparison of ultrasound results between different muscles or different 
subjects, echo intensity and muscle thickness are often expressed as z-scores (the number 
of standard deviations a value deviates from normal). To do so, normal values are 
required. When research for this thesis commenced, normal values were available for 
children26, 31 but not for adults.
Aims of the study
There are several theoretical reasons why ultrasound could be a useful addition to 
the diagnostic armamentarium for ALS. For example, lower MN degeneration leads to 
denervated muscle fibers. Denervation not only results in diminished muscle thick-
ness, but is also associated with increased echo intensity.24 In addition, the presence of 
fasciculations -one of the most characteristic features in ALS- can be detected with high 
sensitivity using ultrasound.
The overall aim of this thesis is to examine the possible usefulness of quantitative muscle 
ultrasonography in ALS. First, normal values for echo intensity, muscle thickness and 
fasciculations are established. Second, ultrasound changes and the corresponding 
histopathological alterations in ALS are described in detail. Finally, prospective studies 
assess the value of muscle ultrasound to make a diagnosis of ALS, predict prognosis 
and monitor disease progression. 
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BOX 3 Quantitative muscle ultrasound scanning
The subject is examined in the supine position with the arms and legs extended and the muscles 
completely relaxed. A generous amount of contact gel is used to minimize the required pressure of the 
transducer on the skin. All scans are made in the transverse plane with a standard transducer location 
corresponding to the largest diameter at the anatomical sites presentented in table B3. 
TABLE B3 Standardized ultrasound protocol
Transducer location
Sternocleidomastoid ½ distance mastoid bone – cranial sternal margin
Biceps brachii ⅔ distance acromion – antecubital crease
Forearm flexors ⅖ distance antecubital crease – distal end radius
Forearm extensors ½ distance antecubital crease – distal end ulna
Quadriceps femoris ½ distance anterior superior iliac spine – superior aspect patella
Tibialis anterior ¼ distance inferior aspect patella – lateral malleolus
Caliper position
Sternocleidomastoid dorsal fascia sternocleidomastoid – ventral fascia sternocleidomastoid
Biceps brachii upper margin humerus – ventral fascia biceps
Forearm flexors interosseus membrane – ventral fascia most superficial flexors
Forearm extensors interosseus membrane – dorsal fascia most superficial flexors
Quadriceps femoris upper margin femoral bone – ventral fascia rectus femoris
Tibialis anterior interosseous membrane – ventral fascia tibialis anterior 
Muscle Thickness
Muscle thickness is determined with electronic calipers during the ultrasound examination. The 
localization of the calipers are presented in Table B3. An example of thickness measure ment is shown 
in Figure B3. 
Pitfalls
The biggest pitfall is compression of the muscle by pressure of the probe, leading to lower muscle 
thickness. An incorrect larger diameter will be measured when muscles are not fully relaxed or when 
muscles are scanned oblique. 
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Echo Intensity
For quantitative echo intensity assessment, three consecutive measurements are taken of each muscle 
to minimize variation in echo intensity. The ultrasound images are stored for further offline evaluation. 
Using customized image analysis software -for example the program developed at our department 
(Qumia, www.qumia.nl)- a region of interest is selected in each muscle image. This region of interest 
includes as much of the muscle as possible without any bone or surrounding tissue (figure B3). The 
mean echo intensity of this region was calculated and averaged over the three measurements per 
muscle. The echo intensity is similar to the average density of white pixels, and is expressed as a value 
between 0 (= black) and 255 (= white).
FIGURE B3 
An example of an ultrasound scan of the biceps brachii. The right panel depicts the different structures 
schematically. The dotted lasso represents the region of interest for echo intensity determination. 
Muscle thickness is symbolized by the arrow.  
Pitfalls
Echo intensity is dependent on the ultrasound device and its settings. Therefore the settings should be 
kept constant. It is possible to compare the results of different ultrasound devices after application of 
an conversion procedure.1 
Oblique scanning can lead to incorrect echo intensity and can be avoided by adjusting the angle of 
measurement until the best bone echo of the underlying bone is obtained. Compression of the muscle 
by to much pressure on the probe can lead to a higher echo intensity and should be prevented.
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Fasciculations
For each muscle a 10 second movie is recorded and stored for further evaluation offline. Movements 
are classified as fasciculations if they appeared as twitching of small parts of the muscle for at least 
two times. Fasciculations are scored in a semiquantitative fashion: 0 = no fasciculations, 1 = sporadic 
fasciculations (at least two), 2 = fasciculations on a regular basis, 3 = continuous fasciculations with 
the muscle moving nearly constantly. 
Pitfalls
Fasciculations should be distinguished from other muscle movements. Arterial pulsations are unifocal 
and ritmic. Voluntary movements, cramp and tremor involves the entire muscle. Fibrillations are very 
fine diffuse non-jerky oscillating movements. 
More information
For more information on muscle ultrasound measurements, conversion procedures and hands-on 
courses:
• www.qumia.nl
• Quantitative muscle ultrasound in childhood neuromuscular disorders. Thesis  
Sigrid Pillen (2009). Radboud University Nijmegen, Nijmegen, The Netherlands  
(sigridpillen@gmail.com)
• Department of Clinical Neurophysiology, Radboud University Nijmegen Medical Centre.   
Telephone: +31 24 3613973
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INTRODUCTION
Sarcopenia, the age-related decline in muscle mass, is an important physical feature 
of growing old. It is thought to result from a complex interplay between neurological, 
metabolic, hormonal, nutritional and physical-activity related changes.1 The loss of muscle 
mass and strength is associated with an increased tendency to fall, dependency, nursing 
home admission and mortality.2, 3 Sarcopenia can be partially reversed by resistance 
training interventions, even in the very old.4 Previous studies examined the effect of aging 
on muscle size predominantly in elderly subjects. In this study, the rise and fall of muscle 
size across the entire life span was established by measuring muscle diameter in 
subjects between 0 and 90.
 
METHODS
A cross-sectional study was conducted in which the thickness of the biceps brachii 
and quadriceps femoris muscles were measured in 194 healthy volunteers (103 male 
subjects). Age ranged from 2 months to 90 years, with at least six males and six females 
per decade. All elderly subjects were still physically active and functionally independent 
and walked without a walking aid. The local ethics committee approved the study, and 
informed consent was obtained from all participants or their parents.
Ultrasound was performed using a phased-array real-time scanner with a 7.5-MHz 
transducer (Sonos 2000 Phased Array Imaging System; Hewlett-Packard, Andover, 
Massachusetts). The patient was put in a supine position with the arms and legs extended 
and the muscles completely relaxed. A generous amount of contact gel was used to 
minimize the required pressure of the transducer on the skin. Transverse ultrasound 
images were made at the muscle belly (biceps brachii: two-thirds of the distance from the 
acromion to the antecubital crease; quadriceps femoris: halfway along the line from the 
anterior superior iliac spine to the superior aspect of the patella).5 Muscle thickness was 
measured with electronic calipers placed at the superficial fascia and at the underlying 
bone. 
To determine the relationship between age and muscle thickness, a nonlinear regression 
analysis was performed (SPSS version 12.0, Chicago, IL). Because of the asymmetrical 
curve-shaped distribution, a third order polynomial regression equation was used to 
describe the data (y = b0 + b1x
1 + b2x
2 + b3x
3).
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RESULTS
The thickness of the biceps and quadriceps muscles as a function of age and gender 
are shown in figure 1, together with the regression equations. The data were distributed 
according to a asymmetrical parabola. Up to age 20, muscle thickness increased steeply; 
between 25 and 50 peak muscle thickness was reached; and thereafter sarcopenia set 
in. Starting between the first and second decade, men had thicker muscles than women. 
This sex difference was most pronounced in the biceps muscle, although men also had 
a steeper decrease of muscle thickness than women. Between 40 and 90 quadriceps 
muscle thickness declined 50% in men and 30% in women, and biceps muscle thickness 
declined 30% in men and 20% in women. Ultimately, muscle thickness in both men and 
women decreased to a size comparable to infants in the first decade.
FIGURE 1
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Age related changes in thickness of the biceps brachii (A) and the quadriceps femoris (B). 
Overlayed lines represent the fitted polynomial model according to the following equations 
(y=b0 + b1x
1 + b2x
2 + b3x
3):
Biceps muscle thickness male = 
0.858 + ( 0.118 * age) – (1.915 * 10-3 * age2) + (8.546 * 10-6 * age3); R2:0.82, p < .001
Biceps muscle thickness female = 
1.142 + ( 0.064 * age) – (1.130 * 10-3 * age2) + (5.508 * 10-6 * age3); R2:0.51, p < .001
Quadriceps muscle thickness male = 
1.812 + ( 0.171 * age) – (2.996 * 10-3 * age2) + (1.295 * 10-5 * age3); R2:0.67, p < .001
Quadriceps muscle thickness female = 
2.081 + ( 0.133 * age) – (2.744 * 10-3 * age2) + (1.521 * 10-5 * age3); R2:0.41, p < .001 
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DISCUSSION
This study showed the striking prevalence and severity of muscle loss due to aging: the 
thickness of the quadriceps muscle of a 90-year-old man is similar to that of a 5-year-old 
child. All studied subjects were healthy and physically active, even up to the highest 
ages, indicating that sarcopenia in the general population will even be more pronounced. 
Loss of muscle mass is the largest contributing factor to the decline in strength with age 
and is caused mainly by a decrease in muscle fiber size in combination with reduced 
number of muscle fibers.6 In addition, the number of muscle fibers per unit muscle mass 
decreases.6 A reduction in motor axons is the primary cause of this fall in muscle density.7 
Decreased muscle density leads to a further decline in muscle strength than explained 
by atrophy alone, because muscle thickness may be relatively spared because of to 
fatty and fibrous muscle infiltration.6, 8 Examining the results and taken into consideration 
that adults have to bear more weight than their 5-year-old counterparts, it is striking that 
90-year-old men are still able to walk independently.
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 ABSTRACT
Ultrasonography can detect structural muscle changes caused by neuromuscular 
disease. Quantitative analysis is the preferred method to determine if ultrasonography 
findings are within normal limits, but normative data are incomplete. The purpose of this 
study was to provide normative muscle ultrasonography data for muscle thickness and 
echo intensity for five different muscle groups in adults. Bilateral scans of the sterno-
cleidomastoid, biceps brachii, forearm flexors, quadriceps femoris and tibialis anterior 
were made in 95 volunteers aged 17-90 years. Both muscle thickness and echo intensity 
showed gender differences and a muscle specific non-linear correlation with age. The 
muscles of the upper extremities showed right-left differences. These data demonstrate 
the effect of age on muscle characteristics and provide normative values that can be 
used in clinical practice.
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INTRODUCTION
Since 1980, several studies have shown that muscles affected by a neuromuscular 
disease have a distinctive appearance when visualized with ultrasonography.1-4 Besides 
a diminished muscle thickness, affected muscles also appear more white (i.e. have an 
increased echo intensity). This higher echo intensity is the result of increased intramuscular 
fibrous and fatty tissue.5, 6 Muscle abnormalities as detected by ultrasonography have 
now been described in a variety of neuromuscular disorders, such as myositis, motor 
neuron disease, muscular dystrophy, congenital myopathy and polyneuropathy.3, 4, 7-12 
These data suggest that ultrasonography can be used in the formal diagnostic work-up 
for these disorders. For example, it may aid in the discrimination between neuro muscular 
diseases and non-neuromuscular diseases, or between neurogenic disorders and 
myopathies. It can also be used as a screening tool to select patients who need further 
invasive tests or to determine which muscle is most suitable for biopsy. 
Besides pathology, normal aging also influences both muscle thickness and muscle 
structure.13, 14 The process of age-related muscle decline is called sarcopenia and can be 
impressive; reductions in muscle thickness of about 50% have been reported.15 In addition, 
age-related increases in intramuscular fat and fibrous tissue have been described, 
suggesting that echo intensity may also change with age.16, 17 Sarcopenia affects men 
and women to different degrees, and it varies between different muscle groups.16, 18
Initially, muscle thickness and echo intensity were scored visually in a semiquantitative 
way. For the latter, a four-point scale developed by Heckmatt et al. was often used.2 
However, tools for computerized quantitative analyses have been developed and are 
evolving as the current standard. Quantitative analysis of echo intensity can be achieved by 
computer-aided gray-scale analysis.19 This technique is more objective than visual scoring 
and depends less on the experience of the examiner.20 Moreover, it is more sensitive to 
subtle changes in muscle structure. Finally, it allows comprehensive statistical analysis. 
To implement quantitative muscle ultrasonography as a diagnostic tool, data on normal 
values for both muscle thickness and echo intensity are needed. Furthermore, these data 
are required for both genders, across the whole lifespan, and for different muscle groups. 
In children, normative data are now readily available.19, 21 The few studies that have 
presented normal values in adults were restricted by either a small control group, a limited 
number of muscles, or absence of normal values for echo intensity. 22, 23, 11 
In this study, we describe normative data for both muscle thickness and echo 
intensity for five muscle groups on both sides: the sternocleidomastoid; biceps brachii; 
forearm flexors; quadriceps femoris; and tibialis anterior. Data were obtained in a cohort of 
95 volunteers between 17 and 90 years of age. 
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METHODS 
Subjects
Healthy volunteers were recruited by advertisement. At least 6 males and 6 females 
were included in each of the following age groups: 15-29, 30-39, 40-49, 50-59, 60-69, 
70-79 and ≥80 years. They were all healthy and able to walk without an assistive device. 
None of the volunteers had a history of limb-surgery (stitches and muscle- and nerve 
sparing minor surgery excluded), hereditary neuromuscular disorders, neuromuscular 
complaints (including radicular syndromes), or diabetes mellitus (because of a high risk 
of concomitant polyneuropathy). The study was approved by the local ethics committee, 
and informed consent was obtained from all participants.
Ultrasonography measurements 
The ultrasonography examinations were performed by either one of the present 
investigators (I.A.) or a trained clinical neurophysiology technician. All measure-
ments were done using a phased-array real-time scanner with a 7.5-MHz transducer 
(Sonos 2000 Phased Array Imaging System; Hewlett-Packard, Andover, Massachusetts). 
Equipment settings including gain (86 dB), compression (70 dB) and time gain 
compensation were identical to our previous studies and were initially based on a pilot 
study that included healthy volunteers and a number of patients with neuromuscular 
disorders.1, 19 All equipment settings were kept constant. For measurement of muscle 
thickness only, the depth setting (initially set at 4 cm) was allowed to change during 
examination in order to display the entire muscle. The resulting pictures were stored as 
TIFF files and had a resolution of 720 x 512 pixels (8-bit, 256 gray scale levels). 
Ultrasonography scans were made of the following muscles or muscle groups on both 
sides: sternocleidomastoid; biceps brachii, including the underlying brachialis muscle; 
forearm flexor group; quadriceps femoris; and tibialis anterior. The subject was examined 
in the supine position with the arms and legs extended and the muscles completely 
relaxed. A generous amount of contact gel was used to minimize the required pressure of 
the transducer on the skin. All scans were made in the transverse plane with a standard 
transducer location corresponding to the largest diameter at the following anatomical 
sites: the sternocleidomastoid muscle was measured halfway along the line from the 
mastoid bone to the clavicular margin; the biceps brachii muscle at two-thirds of the 
distance from the acromion to the antecubital crease; the forearm flexors at two-fifths of 
the distance from the antecubital crease to the distal end of the radius; the quadriceps 
femoris muscle halfway along the line from the anterior-superior iliac spine to the superior 
aspect of the patella; and the tibialis anterior muscle at one-quarter of the distance from 
the inferior aspect of the patella to the lateral malleolus. The whole protocol took about 
60 minutes, 40 minutes for the measurements and 20 minutes for echo intensity analysis. 
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For each muscle three consecutive measurements were taken to minimize variation 
in echo intensity. Oblique scanning can lead to incorrect muscle thickness and echo 
intensity and was avoided by adjusting the angle of measurement until the best bone 
echo of the underlying bone was obtained.
Measurement of muscle thickness
Muscle thickness was measured with electronic calipers placed at standard locations 
(Figure 1). The sternocleidomastoid muscle was measured next to the jugular vein 
between the dorsal muscle fascia and the ventral muscle fascia; the biceps brachii 
muscle (including the underlying brachialis muscle) between the uppermost part of the 
bone echo of the humerus and the superficial fascia of the biceps; the forearm flexors 
between the interosseous membrane (next to the radius) and the superficial fascia of the 
most ventral flexors; the quadriceps femoris between the uppermost part of the bone 
echo of the femur and the superficial fascia of the rectus femoris (which includes the 
rectus femoris and vastus intermedius); and the tibialis anterior between the interosseous 
membrane (next to the tibia) and the superficial fascia of the tibialis anterior.
Measurement of echo intensity
Echo intensity was determined with computer-assisted gray-scale analysis using the 
standard histogram function in Adobe Photoshop 7.0 (Adobe Systems Inc., San Jose, 
California). A region of interest was selected in each muscle to include as much of the 
muscle as possible without any bone or surrounding fascia (Figure 1). For echo intensity 
analysis, the depth setting was fixed at 4 cm. When this setting was insufficient to display 
the entire muscle, only the superficial part of the muscle was used for echo intensity 
analysis. The mean echo intensity of the region of interest was calculated (8 bit 
resolution, resulting in a number between 0 and 255, where black = 0, white = 255) and 
averaged over the three measurements per muscle. In the upper arm, only the biceps 
brachii was included for echo intensity measurements in order to prevent inclusion of the 
(high intensity) fascia which separates the biceps from the brachialis. In the quadriceps 
femoris, the rectus femoris muscle was used for analysis, because the outlines of the 
vastus intermedius muscle can be difficult to define in certain neuromuscular disorders. 
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FIGURE 1
Example of ultrasonography scans of the sternocleidomastoid (A), biceps brachii (B), forearm flexors 
(C), quadriceps femoris (D), and tibialis anterior (E). The right panel depicts the different structures 
schematically. The dotted, gray, lasso represents the region of interest for echo intensity determination of 
each muscle. Muscle thickness is symbolized by the dotted, gray arrow. For the example of the scan of 
the quadriceps a depth setting of 6 cm was used. For determination of the echo intensity the depth setting 
has to be changed to 4 cm. 
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Analysis
Data were analyzed using SPSS for Windows 16.0 (SPSS Inc., Chicago, Illinois, USA). 
Data are shown as mean (SD). Statistical significance was defined as a p-value < 0.05. 
Each muscle was studied separately for men and women. Paired t-tests were applied to 
analyze left-right differences. Muscle thickness was log transformed (using the natural 
logarithm) to remove the skewness in the data. Multiple regression equations were 
calculated to study which covariate influenced muscle thickness and echo intensity. For 
this analysis, data from both sides of each patient were used. Age, height, weight and 
side of measurement were included as covariates. After correcting for the correlated 
covariates, standard deviations were calculated for the residual muscle thickness and 
echo intensity. 
RESULTS
Subjects
Ninety-five volunteers were included (47 males, Table 1). Age ranged between 17 and 
90 years. Mean height for males was 177.8 (6.1) cm and 166.2 (5.5) cm for females. The 
mean weight was 80.5 (12.0) kg for males and 68.6 (11.0) kg for females. All subjects 
were of western European descent.
TABLE 1 Demographic characteristics
Age group Number Length (cm) Weight (cm)
M F M F M F
15-29 8 10 179.5 (5.9) 169.6 (5.5) 72.3 (s12.3) 58.6 (5.2)
30-39 7 6 181.3 (4.8) 167.5 (5.4) 83.6 (14.7) 67.2 (10.0)
40-49 6 6 178.8 (5.8) 170.0 (4.4) 85.0 (15.7) 67.2 (7.6)
50-59 7 6 179.0 (4.4) 164.0 (2.6) 84.3 (16.6) 71.2 (12.0)
60-69 7 7 175.3 (5.2) 164.0 (4.9) 81.9 (7.7) 74.1 (10.3)
70-79 6 6 178.8 (7.1) 165.0 (6.3) 81.5 (3.1) 80.5 (10.2)
≥80 6 7 171.2 (6.0) 162.0 (5.0) 72.5 (2.6) 67.4 (10.5)
Total 47 48 177.8 (6.1) 166.2 (5.5) 80.5 (12.0) 68.6 (11.0)
Data shown as mean (SD). M; male, F; female
Muscle thickness
Mean muscle thickness for each muscle and gender is shown in Table 2. In males, muscle 
thickness was significantly higher in all muscles. There were significant right-left differences 
in the biceps brachii for both males and females, and in the forearm flexor in females. The 
normal ranges in difference between the left and right side are shown in Table 3. 
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TABLE 2 Muscle thickness for each muscle
Muscle group  Muscle thickness (cm)
Male Female
p-value
male vs female
Sternocleidomastoid L 1.03 (0.17) 0.87 (0.15) <0.001
R 1.01 (0.17) 0.87 (0.15) 0.002
Biceps brachii L 2.76 (0.42)* 2.02 (0.35)* <0.001
R 2.96 (0.44)* 2.19 (0.36)* <0.001
Forearm flexors L 3.01 (0.35) 2.32 (0.31)* <0.001
R 3.04 (0.42) 2.44 (0.30)* <0.001
Quadriceps femoris L 4.07 (0.97) 3.57 (0.72) 0.009
R 4.16 (1.02) 3.64 (0.76) 0.009
Tibialis anterior L 2.52 (0.37) 2.17 (0.25) <0.001
R 2.53 (0.31) 2.15 (0.24) <0.001
Data shown mean (SD). * significant difference between left and right. L; left, R; right 
TABLE 3 Normal range of right-left differences in muscle thickness and echo intensity
Muscle group Muscle thickness (cm) Echo intensity
Male Female Male Female
SCM -0.34 – 0.34 -0.24 – 0.24 -13.6 – 13.6 -15.6 – 15.6
Biceps -0.40 – 0.80 -0.25 – 0.59 -12.7 – 12.7 -19.1 – 9.0
Forearm flexor -0.48 – 0.48 -0.28 – 0.52 -9.9 – 9.9 -13.5 – 9.2
Quadriceps femoris -1.0 – 1.0 -0.74 – 0.74 -10.0 – 10.0 -10.8 – 10.8
Tibial -0.46 – 0.46 -0.56 – 0.56 -15.6 – 11.3 -12.5 – 12.5
Data represent -2 SD to + 2 SD from the mean right – left difference in each muscle group
After log transformation, multiple regression equations were calculated. Age and side of 
measurement, but not height, were significant predictors of muscle thickness. The influence 
of these predictors varied between males and females and in the different muscle groups. 
For example, males not only have thicker muscles but also a larger age-related decline. 
The models with the best fit are shown in Figure 2. 
The corresponding model equations and statistical tests are listed in Table 4. All muscles 
showed a non-linear correlation with age. For the tibialis anterior in females, no significant 
correlating model was found, so in practice the mean muscle thickness (2.16 cm) and SD 
(0.25) can be used across all ages. Age-adjusted normative data for muscle thickness of 
each muscle group have been included as supplementary data to this article.
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FIGURE 2
Muscle thickness (cm) as a function of age (yr) and gender together with the regression lines for 
calculated mean muscle thickness. The regression equation for calculated mean is represented by 
the thick line, the equations for +2 and -2 SD with the thin line. When models differed between sides, 
regression lines for the left are shown in gray and for the right in black. The filled squares correspond to 
the right side, the open squares to the left side.  
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FIGURE 3
Echo intensity as a function of age (yr) and gender together with the regression lines for calculated 
mean echo intensity. The regression equation for calculated mean is represented by the thick line, the 
equations for +2 and -2 SD with the thin line. When models differed between sides, regression lines for 
the left are shown in gray and for the right in black. The filled squares correspond to the right side, the 
open squares to the left side.  
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TABLE 4 Equation of the non linear regression model for muscle thickness
Ln(MT) = C + (α ⋅ age) + (β ⋅ age²) + (γ ⋅ age ³) + (δ ⋅ side)
Males
Muscle group C α β γ δ R²  Ln SD p
SCM 0.056 0 0 -2.180 ⋅ 10-7 0 0.089 0.157 0.041
Biceps 0.415 0.047 -8.07 ⋅ 10-4 3.790 ⋅ 10-6 -0.071 0.721 0.106 <0.001
Forearm flexors 0.284 0.055 -9.99 ⋅ 10-4 5.278 ⋅ 10-6 0 0.490 0.098 <0.001
Quadriceps 1.018 0.033 -5.49 ⋅ 10-4 1.747 ⋅ 10-6 0 0.691 0.155 <0.001
Tibial 0.959 0 0 -1.900 ⋅ 10-7 0 0.084 0.131 0.05
Females
Muscle group C α β γ δ R²  Ln SD p
SCM -0.290 0 1.75 ⋅ 10-4 -2.000 ⋅ 10-6 0 0.135 0.174 0.038
Biceps 0.754 0 1.68 ⋅ 10-4 -2.040 ⋅ 10-6 -0.081 0.474 0.150 <0.001
Forearm flexors 0.913 0 8.08 ⋅ 10-5 -1.060 ⋅ 10-6 -0.054 0.411 0.116 0.03
Quadriceps 1.760 -0.025 5.05 ⋅ 10-4 -3.660 ⋅ 10-6 0 0.364 0.178 <0.001
Tibial* Mean: 2.16 SD 0.25
C = constant, α, β, γ and δ are coefficients. Side: right = 1, left = 2. SCM; sternocleidomastoid
*no significant regression model was found
After correction for age, gender and side of measurement, the residual muscle thickness 
showed a correlation with weight. The R2 for the biceps (both males and females) and 
the forearm flexor group (males) was 0.15 and the quadriceps (females) 0.25. The R2 of 
all other muscles was less than 0.10.
Echo intensity
In all muscles, mean echo intensity was higher for females (Table 5). There were 
significant right-left differences in echo intensity in the following muscles: the tibialis 
anterior in males and the forearm flexors and the biceps brachii in females (Table 5). 
The normal ranges of right-left difference in echo intensity are shown in Table 3. Multiple 
regression analyses revealed that, for all muscles, except for the sternocleidomastoid 
muscle in females, echo intensity correlated with age. In case of nonlinearity a quadratic 
and cubic age term was added. The models with the best fit are represented in Figure 3. 
For the sternocleidomastoid muscle in females, no significant regression model was 
found; the mean echo intensity was 32.10 (8.85). 
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TABLE 5 Echo intensity for each muscle
Muscle group Echo intensity (SD)
Male Female
p-value
male vs female
Sternocleidomastoid L 27.08 (8.50) 31.49 (9.51) 0.07
R 27.42 (8.15) 32.71 (8.21) <0.001
Biceps brachii L 29.95 (11.26) 38.21 (10.14)* <0.001
R 28.11 (9.94) 33.18 (8.62)* 0.031
Forearm flexors L 29.40 (8.61) 36.34 (7.33)* <0.001
R 28.63 (8.29) 34.23 (7.29)* 0.002
Quadriceps femoris L 25.30 (8.85) 29.63 (7.89) 0.009
R 26.42 (10.52) 30.45 (7.57) 0.004
Tibialis anterior L 33.92 (9.34)* 39.73 (7.20) <0.001
R 31.77 (7.44)* 38.00 (8.10) 0.002
Data shown mean (SD). * Significant difference between left and right. L; left, R; right 
DISCUSSION
In this study we present normative data for muscle thickness and echo intensity for multiple 
muscles and illustrate the impact of age on muscle characteristics. Men were shown 
to have thicker muscles and lower echo intensity than women. Both muscle thickness 
and echo intensity were correlated with age. The upper limb musculature and the tibialis 
anterior also demonstrated left-right difference in muscle thickness or echo intensity. 
The data illustrate that age related decline in muscle thickness was different for men 
and women, ranging from approximately 0% to 50% depending on the muscle studied 
(Figure 2). The tibialis anterior showed no age related decrease in females and almost 
no decrease in males. The muscle fibers of this muscle are arranged like a feather and 
are therefore scanned more longitudinally. Because aging results in diminished thickness 
but not in shortening of muscle fibers, the tibialis anterior thickness may look relatively 
spared when measured with this method. The measured muscle groups of the arms, but 
not of the legs, showed right-left differences in muscle thickness. These differences were 
probably due to hand dominance. Because only five subjects were left-handed, we could 
not formally test this hypothesis in the current study. 
The age-related increase in echo intensity was also gender- and muscle-dependent. In 
females, the sternocleidomastoid muscle did not show a significant increase of echo 
intensity with age. The slight increase that is suggested in Figure 3 was probably due to 
a larger variation in measurements, which may have been caused by the relative difficulty 
in scanning absolutely perpendicular in the sternocleidomastoid muscle.  
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In contrast to adults, children show no gender-dependent differences in muscle thick-
ness and echo intensity. These gender differences seem to start from puberty and are 
different for upper extremity and lower extremity muscle groups.24 Furthermore, there is 
no age-related increase of echo intensity in children. Our data show that this increase 
predominantly takes place from the age of 60 years. It is known that in the elderly, muscle 
tissue develops increased fatty infiltration, which leads to increases in echo intensity.16
The relation between age and muscle thickness turned out to be curvilinear. This is in 
concordance with age-influenced muscle mass, cross sectional area and muscle strength 
in previous studies.17, 18, 25 However, previous ultrasonography studies reported a linear 
relation between age and muscle thickness.11, 23 A possible explanation for this discrepancy 
could be that those studies had an underrepresentation of subjects in the ascending or 
descending part of the curve shown in Figure 2, thus suggesting a linear correlation. 
 
Using regression equations with age, gender and side as variables, a large part of the 
variability in muscle thickness and echo intensity was explained in most muscles. These 
variables accounted for up to 70% of the variability in muscle thickness in men and 50% 
in women, and 50% of the echo intensity in men and 44% in women. After correction for 
these variables, weight still explained 5-25% of the residual variation in muscle thickness. 
We propose not to include weight as a variable in the regression equations, because 
some neuromuscular diseases will lead to weight loss due to decline of muscle tissue. 
Correction for weight therefore leads to correction for pathology, which may lead to false-
negative outcomes when muscle thickness is assessed.
The normative data in this study encompass five different muscle groups: a proximal and 
distal muscle group in both the upper and lower limb, and one bulbar muscle. These 
muscle groups were chosen to provide information on the pattern of affected muscles. 
As different neuromuscular diseases present with typical patterns of muscle involvement, 
information on distal, proximal or bulbar involvement, as well as symmetry, can be of 
differential diagnostic value. 
The measurement of muscle thickness does not depend on equipment settings. There-
fore, normative data of muscle thickness presented in this study can be applied in other 
centers. Because we studied a homogeneous population of western European descent, 
care has to be taken when applying our normal values to different populations. 
Echo intensity values do differ between ultrasound devices. Our normative echo intensity 
values can only be used with the same ultrasound device and settings; in other cases 
new values must be established. Recently a method was reported to convert echo intensity 
from one ultrasonography device to another,26 which may facilitate the distribution of 
normal values to centers with different types of ultrasound devices.  
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Ultrasonography is an easy and painless method to analyze muscles for structural 
abnormalities caused by neuromuscular disease, although a number of limitations 
remain. Ultrasonography is less suitable to analyze deeper structures due to attenuation 
of the ultrasonography beam in overlying tissue by reflection, dispersion and absorption 
of the sound. Furthermore, selective involvement of one part of a muscle group is 
relatively difficult to visualize using ultrasonography, mainly because of the relatively 
narrow range of view. In these situations magenetic resonance imaging (MRI) prevails. 
Future studies can use these normative data to describe and compare the ultrasound 
characteristics of different neuromuscular diseases in order to assess the differential 
diagnostic value. In addition, because ultrasonography is a non-invasive and easily 
accessible technique that gives no radiation exposure, it represents a promising method 
to monitor disease progression or evaluate treatment effect.
 
Normal values for muscle thickness and echo intensity 43Normal values for muscle thickness and echo intensity
REFERENCES
1.  Pillen S, Scholten RR, Zwarts MJ, Verrips A. Quantitative skeletal muscle ultrasonography in children 
with suspected neuromuscular disease. Muscle Nerve 2003; 27:699-705.
2.  Heckmatt JZ, Leeman S, Dubowitz V. Ultrasound imaging in the diagnosis of muscle disease. J Pediatr 
1982; 101:656-660.
3.  Walker FO, Cartwright MS, Wiesler ER, Caress J. Ultrasound of nerve and muscle. Clin Neurophysiol 
2004; 115:495-507.
4.  Arts IM, van Rooij FG, Overeem S, Pillen S, Janssen HM, Schelhaas HJ, et al. Quantitative muscle 
ultrasonography in amyotrophic lateral sclerosis. Ultrasound Med Biol 2008; 34:354-361.
5.  Reimers K, Reimers CD, Wagner S, Paetzke I, Pongratz DE. Skeletal muscle sonography: a correlative 
study of echogenicity and morphology. J Ultrasound Med 1993; 12:73-77.
6.  Pillen S, Tak RO, Zwarts MJ, Lammens MY, Verrijp KN, Arts IMP, et al. Skeletal muscle ultrasound: 
correlation between fibrous tissue and echo intensity. Ultrasound Med Biol 2009; 35:443-446.
7.  Pillen S, Arts IM, Zwarts MJ. Muscle ultrasound in neuromuscular disorders. Muscle Nerve 2008; 
37:679-693.
8.  Bargfrede M, Schwennicke A, Tumani H, Reimers CD. Quantitative ultrasonography in focal neuro-
pathies as compared to clinical and EMG findings. Eur J Ultrasound 1999; 10:21-29.
9.  Fischer AQ, Carpenter DW, Hartlage PL, Carroll JE, Stephens S. Muscle imaging in neuromuscular 
disease using computerized real-time sonography. Muscle Nerve 1988; 11:270-275.
10.  Gunreben G, Bogdahn U. Real-time sonography of acute and chronic muscle denervation. Muscle 
Nerve 1991; 14:654-664.
11.  Reimers CD, Schlotter B, Eicke BM, Witt TN. Calf enlargement in neuromuscular diseases: a quantitative 
ultrasound study in 350 patients and review of the literature. J Neurol Sci 1996; 143:46-56.
12.  Zuberi SM, Matta N, Nawaz S, Stephenson JB, McWilliam RC, Hollman A. Muscle ultrasound in the 
assessment of suspected neuromuscular disease in childhood. Neuromuscul Disord 1999; 9:203-207.
13.  Roubenoff R, Castaneda C. Sarcopenia-understanding the dynamics of aging muscle. JAMA 2001; 
286:1230-1231.
14.  Doherty TJ. Invited review: Aging and sarcopenia. J Appl Physiol 2003; 95:1717-1727.
15.  Arts IM, Pillen S, Overeem S, Schelhaas HJ, Zwarts MJ. Rise and fall of skeletal muscle size over the 
entire life span. J Am Geriatr Soc 2007; 55:1150-1152.
16.  Goodpaster BH, Carlson CL, Visser M, Kelley DE, Scherzinger A, Harris TB, et al. Attenuation of 
skeletal muscle and strength in the elderly: The Health ABC Study. J Appl Physiol 2001; 90:2157-2165.
17.  Lexell J, Taylor CC, Sjostrom M. What is the cause of the ageing atrophy? Total number, size and 
proportion of different fiber types studied in whole vastus lateralis muscle from 15- to 83-year-old men. 
J Neurol Sci 1988; 84:275-294.
18.  Janssen I, Heymsfield SB, Wang ZM, Ross R. Skeletal muscle mass and distribution in 468 men and 
women aged 18-88 yr. J Appl Physiol 2000; 89:81-88.
19.  Scholten RR, Pillen S, Verrips A, Zwarts MJ. Quantitative ultrasonography of skeletal muscles in 
children: normal values. Muscle Nerve 2003; 27:693-698.
44 Normal values for muscle thickness and echo intensity Normal values for muscle thickness and echo intensity
20.  Pillen S, van Keimpema M., Nievelstein RA, Verrips A, Kruijsbergen-Raijmann W, Zwarts MJ. 
Skeletal muscle ultrasonography: Visual versus quantitative evaluation. Ultrasound Med Biol 2006; 
32:1315-1321.
21.  Maurits NM, Beenakker EA, van Schaik DE, Fock JM, van der Hoeven JH. Muscle ultrasound in 
children: normal values and application to neuromuscular disorders. Ultrasound Med Biol 2004; 
30:1017-1027.
22.  Maurits NM, Bollen AE, Windhausen A, De Jager AE, van der Hoeven JH. Muscle ultrasound analysis: 
normal values and differentiation between myopathies and neuropathies. Ultrasound Med Biol 2003; 
29:215-225.
23.  Reimers CD, Harder T, Saxe H. Age-related muscle atrophy does not affect all muscles and can partly 
be compensated by physical activity: an ultrasound study. J Neurol Sci 1998; 159:60-66.
24.  Kanehisa H, Ikegawa S, Tsunoda N, Fukunaga T. Cross-sectional areas of fat and muscle in limbs 
during growth and middle age. Int J Sports Med 1994; 15:420-425.
25.  Kallman DA, Plato CC, Tobin JD. The role of muscle loss in the age-related decline of grip strength: 
cross-sectional and longitudinal perspectives. J Gerontol 1990; 45:M82-M88.
26.  Pillen S, van Dijk JP, Weijers G, Raijmann W, de Korte CL, Zwarts MJ. Quantitative gray-scale analysis 
in skeletal muscle ultrasound: a comparison study of two ultrasound devices. Muscle Nerve 2009; 
39:781-786.
Normal values for muscle thickness and echo intensity 45Normal values for muscle thickness and echo intensity
SUPPLEMENTARY TABLE Muscle thickness for each muscle group per age cohort 
Male
Age cohort Muscle thickness (cm) for each muscle group
SCM Biceps L Biceps R F. Flexor Quadriceps Tibial
15-29 (n = 8) 1.0 (0.13) 2.7 (0.42) 2.9 (0.37) 3.0 (0.29) 4.7 (0.52) 2.6 (0.41)
30-39 (n = 7) 1.0 (0.19) 3.0 (0.28) 3.2 (0.39) 3.3 (0.16) 4.7 (0.93) 2.6 (0.37)
40-49 (n = 6) 1.0 (0.09) 3.2 (0.37) 3.2 (0.34) 3.3 (0.30) 4.6 (0.59) 2.4 (0.34)
50-59 (n = 7) 1.1 (0.18) 2.9 (0.42) 3.2 (0.51) 3.3 (0.41) 4.7 (0.66) 2.7 (0.28)
60-69 (n = 7) 1.1 (0.18) 2.8 (0.19) 2.9 (0.25) 3.0 (0.23) 4.1 (0.67) 2.6 (0.22)
70-79 (n = 6) 0.9 (0.17) 2.5 (0.20) 2.7 (0.34) 2.8 (0.45) 3.0 (0.42) 2.3 (0.25)
≥ 80 (n = 6) 1.0 (0.18) 2.2 (0.11) 2.4 (0.31) 2.6 (0.26) 2.7 (0.50) 2.3 (0.32)
Female
SCM Biceps L Biceps R F. Flexor L F. Flexor R Quadriceps Tibial
15-29 (n =10) 0.8 (0.12) 1.9 (0.26) 2.1 (0.25) 2.4 (0.30) 2.5 (0.23) 4.1 (0.47) 2.2 (0.23)
30-39 (n = 6) 1.0 (0.12) 2.1 (0.22) 2.2 (0.40) 2.3 (0.30) 2.5 (0.20) 4.0 (0.58) 2.2 (0.31)
40-49 (n = 6) 0.8 (0.13) 2.1 (0.41) 2.3 (0.34) 2.3 (0.31) 2.5 (0.24) 3.6 (0.46) 2.1 (0.32)
50-59 (n = 6) 0.9 (0.14) 2.2 (0.44) 2.3 (0.44) 2.4 (0.30) 2.5 (0.26) 3.7 (0.59) 2.2 (0.24)
60-69 (n = 7) 1.0 (0.13) 2.1 (0.39) 2.4 (0.46) 2.4 (0.35) 2.4 (0.33) 3.6 (0.85) 2.2 (0.20)
70-79 (n = 6) 0.9 (0.09) 2.2 (0.45) 2.3 (0.33) 2.4 (0.40) 2.6 (0.37) 3.4 (0.80) 2.2 (0.21)
≥ 80 (n = 7) 0.8 (0.14) 1.7 (0.06) 1.8 (0.14) 2.1 (0.22) 2.2 (0.30) 2.8 (0.56) 2.1 (0.24)
Data shown mean (sD). SCM; sternocleidomastoid, F.Flexor; forearm flexor, L; left, R; right
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ABSTRACT
Our objective was to determine the prevalence and distribution of fasciculations in 
healthy adults and to assess the effect of age, caffeine and exercise. Fasciculations were 
studied with ultrasonography in 58 healthy adults in various age categories. Question-
naires were used to determine effect of caffeine and regular exercise on the presence 
of fasciculations. Finally, we tested the effect of strenuous exercise on fasciculations in 
10 healthy adults. Twenty-five subjects (43%) showed fasciculations on ultrasonography, 
mostly in the abductor hallucis longus muscle. Fasciculations were only sporadically 
encountered in muscle groups above the knee. Subjects with fasciculations were 
significantly older than those without. Caffeine and regular physical exercise did not 
influence the prevalence of fasciculations. However, strenuous physical exercise caused 
a temporary increase in fasciculations, but only in lower leg muscles. Fasciculations above 
the knee should raise suspicion and may warrant further investigation.
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INTRODUCTION
A fasciculation is clinically defined as a spontaneous intermittent contraction of a portion 
of muscle.1 When assessed with electromyography (EMG), a fasciculation potential is 
defined as a random, spontaneous twitch of a group of muscle fibers belonging to a 
single motor unit.2 When assessed with ultrasound fasciculations are classified as 
involuntary twitching of small parts of the muscle, lasting for 0.2 – 1.0 seconds.3 When 
generated in superficial muscle layers, fasciculations are visible through the skin, whereas 
in deeper layers they are only detectable by ultrasound imaging4-6 or EMG.7
Fasciculations are a clinical hallmark of amyotrophic lateral sclerosis (ALS), especially 
when widespread and accompanied by muscle atrophy.8 However, fasciculations are also 
encountered in various neurogenic disorders like radiculopathy and other neuropathies 
(acquired, inflammatory, entrapment), and benign cramp fasciculation syndrome.9, 10 
Localized fasciculations also occur in healthy individuals.5, 10-13 Using 2-minute EMG- 
recordings, Van der Heijden et al. found fasciculations in all 60 healthy subjects, aged 
18-25 years, in at least one of the abductor hallucis longus muscles.10 However, only 
lower leg muscles were assessed in this study. In a questionnaire study 70% of 539 
subjects reported to experience fasciculations, mainly located in the orbicularis oculi and 
intrinsic hand- and foot- musculature.13 However, these subjective reports may have also 
included other phenomena, such as myokymias.
Increasing age, high caffeine consumption and physical exercise have been suggested 
to cause the appearance of fasciculations in healthy subjects.1, 9, 11, 13 However, none 
of these factors has been systematically studied. Nevertheless, in clinical practice all 
these factors may influence the physician’s decision whether fasciculations should be 
considered normal or pathological, the latter warranting further diagnostic evaluation.
Here, we assessed the prevalence and distribution of fasciculations in healthy adults, 
using ultrasonography, a reliable and non-invasive tool for this purpose.3, 6, 14-18 Scheel 
and Reimers found ultrasonography to be more sensitive than clinical observation and 
EMG, with a sensitivity of respectively 67%, 42% and 38%, respectively.3 In a previous 
study, we demonstrated the relevance of fasciculations, detected by ultrasound in 
the diagnostic work-up of ALS.14 Before proceeding to prospective studies or clinical 
application, specificity was mentioned as a major issue to resolv first. This study was 
constructed to define the range of findings in normal subjects. Furthermore, we studied 
reliability and the influence of age, physical exercise and caffeine on fasciculations.
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METHODS
Set up
Study 1 assessed the prevalence, distribution and influencing factors of fasciculations 
in 58 healthy subjects. Using ultrasonography, the sternocleidomastoid, biceps brachii, 
forearm flexors, quadriceps femoris, tibialis anterior and abductor hallucis longus 
muscles were assessed on both sides. Subjects completed a questionnaire to determine 
the average amount of hours of physical exercise per week, and in the 24 hours before 
ultrasonography, as well as the average units of caffeinated drinks consumed per day 
and on the day of ultrasonography. 
Study 2 was an intervention study in 10 separate subjects, determining the specific effect 
of strenuous physical exercise on fasciculations. In addition, subjects self-reported the 
time-course of fasciculations during three days after the measurement. The gastrocnemius 
muscle was added to the ultrasound protocol in Study 1. Subjects were measured half an 
hour before, and half an hour after, strenuous physical exercise. Strenuous physical exer-
cise was defined as the maximum effort possible in each individual during the maximum 
time-course possible in each individual. Exercise included running, squash, spinning, 
aerobics, or a combination of these sports. To observe the course of fasciculations, a 
fasciculation diary was kept during three days following the exercise. 
Subjects
All participants were healthy and recruited amongst acquaintances and colleagues. 
Elderly participants were mainly recruited at the university sports centre. To optimize 
self-description of the course of fasciculations after exercise, subjects were recruited 
amongst medical doctors in Study 2. Exclusion criteria were: limb-surgery (minor muscle- 
and nerve-sparing surgery excluded), known hereditary neuromuscular disorder in the 
family, neuromuscular complaints, muscle weakness, sensory deficits, radicular syndrome 
and/or diabetes mellitus in the past and/or present. The study was approved by the local 
ethics committee and informed consent was obtained from all participants.
Ultrasound
All subjects were tested supine and instructed to relax their muscles. Ultrasonography 
was performed using a phased array real-time scanner (Philips i-u22, The Netherlands) 
with a 5-17 MHz broadband linear transducer. The frame rate was 20 Hz in all recordings. 
The video recordings were stored and assessed as DICOM files viewing them with 
Acculite 3122. All muscles were measured during 10 seconds.
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Scoring
After measurement the 10-second video recordings were screened for fasciculations. 
Fasciculations were distinguished from other movements detectable with ultrasound, 
such as arterial pulsations and shivering, and were classified as involuntary twitching of 
small parts of the muscle that occurred at least twice within 10 seconds.3 All results were 
reviewed separately by 2 investigators (J.F. and I.A.). Inter-observer agreement on the 
presence of fasciculations was assessed and judged to be good (Cohen’s kappa 0.82). 
Results after reaching consensus were eventually used.
In Study 1, outcome measures per muscle were defined as: 0 = fasciculations absent 
and 1 = fasciculations present. In Study 2, the main goal was to determine progression 
of fasciculations. Outcome measures were therefore defined as: 0 = no fasciculations, 
1 = sporadic fasciculations (at least two), 2 = fasciculations on a regular basis, 
3 = continuous fasciculations with the muscle moving nearly constantly. Progression was 
defined as an increase of at least one category.
Statistics
The SPSS package for Windows 14.0 (SPSS Inc, Chicago, IL, USA) was used for 
statistical analysis. Statistical significance was defined as p< 0.05. Group compari-
sons on continuous variables were made using the independent-samples t-test or the 
Mann-Whitney U-Test, depending on the distribution of the data. Categorical data were 
compared using the c² test. 
RESULTS
Study 1 – prevalence
Demographics
Demographics are displayed in Table 1. Twenty-eight males and 30 females were equally 
distributed over six groups: 20-29, 30-39, 40-49, 50-59, 60-69 and 70 years and older. 
TABLE 1 Demographic characteristics 
Number of subjects 58
Males (%) 28 (48%)
Age (years) 50.2 (22– 93) 
Habitual caffeine use (units per day) 5.1 (0-12) 
Caffeine use on day of examination (units)* 2.5 (0-10) 
Habitual amount of physical exercise (hours per week) 5.5 (0-15) 
Physical exercise on day of examination (hours)* 1.0 (0-8) 
Data are mean (range) or n (%), * prior to examination
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Prevalence and distribution of fasciculations
Twenty-five controls (43%) showed fasciculations in one or more muscles. By far the 
most affected muscle was the abductor hallucis longus, which showed fasciculations in 
22 subjects (38 %). Fifteen subjects (26%) had fasciculations in one abductor hallucis 
longus and seven subjects in both (12%). In all but three subjects, fasciculations were 
only found below the knee (see Figure 1).
FIGURE 1
Absolute number (and percentages) of 58 subjects showing fasciculations in the muscles measured.  
Of these three, one subject showed fasciculations in the biceps brachii on the right, 
the quadriceps femoris on both sides and the tibialis anterior on the right; further-
more fasciculations were found in the abductor hallucis longus on the left. This was 
the only subject with fasciculations in the upper extremities and in this many muscles. 
Approximately three months after our measurements, this subject was admitted by the 
internal medicine department because of elevated liver enzymes, which led to the suspicion 
of alcohol abuse. 
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The other two showed fasciculations in the quadriceps femoris on the right. One of 
them also showed fasciculations in both abductor hallucis longus muscles. These two 
subjects exercised strenuously the day before the ultrasonography, as opposed to the 
other subjects.
Provoking factors
Subjects were divided into a group with and without fasciculations and data were 
compared between these groups. The group with fasciculations was significantly older 
(55 versus 45 years, p = 0.039).There were no differences in the amount of exercise and 
caffeine use between the group with and without fasciculations (see Table 2). 
 
TABLE 2 Comparison of healthy subjects with fasciculations and without fasciculations 
Fasciculations
No  
fasciculations P-value
(n = 25) (n = 33)
Age (years) 55.96 (27-83) 45.85 (22-93) 0.039
Habitual caffeine use (units per day) 5.26 (0.5-10) 4.93 (0-12) 0.659
Caffeine use on day of examination (units)* 2.52 (0-5) 2.52 (0-10) 0.580
Habitual physical exercise per week (hours) 5.86 (0-15) 5.24 (0-15) 0.555
Physical exercise on day of examination (hours)* 1.25 (0-8) 0.89 (0-4) 0.416
Data are mean (range), * prior to examination
Study 2 – exercise
Demographics
We included five males and five females aged 20-40 years. 
Progression of fasciculations
After exercise an increase in fasciculations was seen with ultrasonography in four out 
of five male subjects, but in none of the females. Progression after exercise was only 
found in the gastrocnemius muscle (see Table 3). After three days of self-observation, 
the subjects showing fasciculations on ultrasonography all reported an increase of 
fasciculations in the first 10 hours, after which they decreased. All fasciculations had 
disappeared within 24 hours. 
Three out of five females reported to have had fasciculations in both the gastrocnemius 
and abductor hallucis longus muscles. Fasciculations only start at least 24 hours after 
exercise and disappeared within 6-8 hours.
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TABLE 3  Fasciculations in the gastrocnemius and abductor hallucis muscles before and  
 after strenuous exercise
Pt Gender Age Type of sports Gastrocnemius
abductor  
hallucis longus
Fasc. noticed 
<48 hours
Before After Before After
R L R L R L R L
 1 Female 33 Spinning/Aerobics 0 0 0 0 0 0 0 0 yes
 2 Female 29 Skating/Aerobics 0 0 0 0 0 0 0 0 no
 3 Female 28 Spinning/Aerobics 0 0 0 0 0 0 0 0 yes
 4 Male 27 Squash 0 0 2 1 1 0 1 1 yes
 5 Female 30 Aerobics 0 0 0 0 1 0 1 0 no
 6 Male 39 Running 0 0 0 2 0 1 0 0 yes
 7 Male 37 Running 1 0 3 2 0 1 0 0 yes
 8 Female 30 Running 0 0 0 0 0 0 1 0 yes
 9 Male 35 Running 0 0 0 0 0 0 0 0 no
 10 Male 45 Running 2 0 3 2 2 1 2 1 yes
Abbreviations used: L: left, R: right, Fasc.: fasciculations
Grading (during 10 second measurement): 0 = no fasciculations, 1 = sporadic fasciculations (at least 2), 
2 = fasciculations on a regular basis, 3 = continuous fasciculations with the muscle moving nearly constantly
DISCUSSION
General outcome
Our study shows that more than one fasciculation per 10 seconds in a muscle above 
the knee is rarely encountered in healthy individuals. We therefore suggest that frequent 
fasciculations above the knee should warrant a diagnostic evaluation. There were no 
differences in the use of caffeine and regular exercise between subjects with or without 
fasciculations. However, subjects with fasciculations were approximately 10 years older 
than those without, suggesting that age may be an influencing factor. Finally, strenuous 
exercise did result in a temporary increase in fasciculations.
Prevalence and distribution
Several studies report fasciculations in healthy subjects to be a common 
phenomenon.4, 9-11, 13 Reed and Kurland found a widespread prevalence and distribution 
of fasciculations amongst healthy subjects.13 Seventy per cent of 539 healthy subjects 
reported fasciculations, mostly experienced in the orbicularis oculi and the upper 
extremities (deltoid and intrinsic hand muscles). In general, subjects mentioned that 
duration of fasciculation episodes was less than 1 minute and they were pronounced 
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during periods of stress, fatigue and after exercise. Furthermore, the majority experienced 
fasciculations in intervals longer than two months. The results of this questionnaire 
study need to be interpreted with caution, especially in the light of our current results. 
For example, the subjective nature of a retrospective questionnaire study may result in 
higher estimates of fasciculations. Moreover, many of the reported movements may not 
have been fasciculations at all, but for example myokymias, especially in the orbicularis 
oculi muscle. 
Van der Heijden et al. found fasculations in at least one abductor hallucis longus muscles 
in all 60 healthy subjects studied10, compared to 43% in our study. This difference may be 
due to the fact that electromyography was used, in contrast with ultrasonography in our 
study. Furthermore, there was an important difference in sampling time: we measured 
10 seconds, while van der Heijden et al. sampled during at least 2 minutes. 
Provoking factors
Increasing age and use of caffeine have often been suggested as influencing factors 
for the occurrence of fasciculations.1, 9, 11, 13 In this study, we found that subjects with 
fasciculations were significantly older, confirming the possible effect of age. However, 
caffeine was not an influencing factor in our subjects. Regular physical exercise did not 
appaer to induce fasciculations, either. However, in individuals approaching their maximum 
physical effort, fasciculations did increase; yet again, they were never encountered above 
the knee. There was a somewhat surprising difference in the time-course of fascicu-
lations after exercise between males and females: all men showed fasciculations directly, 
whereas women did experience fasciculations, but only after 24 hours. The cause of this 
difference remains unclear, but one difference in the type of exercise stood out- all but 
one of the male exercisers ran, as opposed to one runner in the female group. 
Further diagnostic evaluation
Frequent fasciculations above the knee are outside the normal range, and warrant further 
evaluation. Obviously, neurogenic changes on needle EMG will reveal the most important 
diagnostic information.1 Characterisation of the fasciculation potentials themselves can 
be relevant, as complex fasciculation potentials are associated with axonal loss.19, 20 The 
place of muscle ultrasound in this setting requires prospective validation with clinical and 
EMG criteria as a reference.21 Widespread fasciculations may serve as a marker for ALS 
and muscle ultrasound can add to the diagnostic confidence by showing fasciculations 
in the deeper muscle layers.
Possible mechanisms
Fasciculations are generated by ectopic activity somewhere along the motor axon.9, 22, 23 
The distal motor axon or the neuromuscular junction seems to be the source of abnormal 
action potentials that excite the muscle. The proximal or distal origin of fasciculations may 
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change with disease progression and can be demonstrated with EMG.24-26 Ultrasound is 
well suited for longitudinal assessment, but can not resolve the fasciculations at the level 
of the motor unit, which is required for pathophysiological studies. 
Axonal degeneration may play a role in the occurrence of fasciculations. This is supported 
by the fact that the abductor hallucis longus was showing by far the largest number of 
fasciculations, and the axons of distal muscles are known to be most susceptible for dege-
nerative changes. Furthermore, this would explain that age is an influencing factor.27, 28 The 
effects of strenuous exercise are not explained by this mechanism, however, all exercise-
induced fasciculations disappeared very quickly. Unaccustomed physical activity and 
training is unlikely to explain our findings, as the strongest increase in fasciculations, both 
self-reported and recorded, was seen in two well trained runners. The effects of exercise 
suggest a role for metabolic stress rather than local damage. This would also explain that 
the gastrocnemius muscle was preferentially affected, especially in runners. In running 
,the gastrocnemius muscle contracts eccentrically, which costs significantly more energy 
compared to concentric activity.29
Conclusion
Frequent fasciculations above the knee are rarely found in healthy individuals, implicating 
that when encountered in clinical practice, they warrant further diagnostic evaluation, 
including EMG. Caffeine consumption and regular exercise do not appaer to be a 
sufficient explanation when frequent fasciculations are found in an otherwise healthy 
subject. Strenuous physical exercise may induce fasciculations in lower leg muscles, 
however. Thus, if a subject with fasciculations exercised vigorously in the days before 
examination, it would be useful to reassess after a week without exercise.
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ABSTRACT
In this study, we examined whether quantitative muscle ultrasonography can detect 
structural muscle changes in early-stage amyotrophic lateral sclerosis (ALS). Bilateral 
transverse scans were made of 5 muscles or muscle groups (sternocleidomastoid, 
biceps brachii, forearm flexors, quadriceps femoris and tibialis anterior muscles) in 48 
patients with ALS. Twenty-five patients were also screened for fasciculations. Quantitative 
analysis revealed a significant increase in echo intensity in all muscles and a decrease in 
muscle thickness of the biceps brachii, forearm flexors and quadriceps femoris on both 
sides. Fasciculations were easy to detect in multiple muscles of all screened patients 
except one. We conclude that quantitative ultrasonography can be used to detect muscle 
changes caused by ALS in an early phase of the disease.
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INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a progressive and fatal disease involving cell death 
of motor neurons in the cerebral cortex, brainstem and spinal cord. The disease course 
is characterized by progressive weakness and muscle atrophy, leading to disability 
and eventually death. The first symptoms are usually focal, but they quickly generalize; 
affecting skeletal, bulbar as well as respiratory muscles. The mean time of survival is 
three years.1
The diagnosis of ALS is based on the presence of a combination of both upper motor 
neuron (MN) and lower MN signs. In 1994, more formal diagnostic criteria were 
developed.2, 3 These so-called El Escorial criteria rely on a combination of upper and 
lower MN signs in the same body region (bulbar, cervical, thoracal and lumbosacral). 
A higher degree of diagnostic certainty can be reached when more body regions are 
affected. In addition, the disease should be progressive and other disorders should be 
excluded. The El Escorial criteria also have a category “probable laboratory supported 
ALS”, in which neurophysiological testing is used to detect involvement of muscles in 
a body region that is clinically not affected. Currently, the only technique to increase 
diagnostic certainty in such way is electromyography (EMG).  
Despite the diagnostic criteria, it often remains difficult to reach a correct diagnosis, 
partly because of the lack of an objective biological marker.4, 5 This is reflected in the 
average delay between symptom onset and final diagnosis, which may be as high as 
16 months, approximately one-third of the expected survival.6-8 Furthermore, the number 
of misdiagnoses is still unacceptably high with a false-negative rate of 27-43%4, 9 
and a false-positive diagnosis in about 8%.10, 11 Therefore, new techniques to detect 
subclinically affected regions are most welcome.
Muscle ultrasonography is an easily accessible, inexpensive and painless method to 
detect changes in muscle thickness and echo intensity.12 Quantification of muscle 
thickness and echo intensity provides a sensitive and specific objective method to 
discriminate between neuromuscular and non-neuromuscular diseases.13-16 Furthermore, 
quantitative muscle ultrasonography can be used complementary to regular physical 
and diagnostic tests in the detection of subclinical muscle pathology.17 In contrast to 
other imaging modalities like computed tomography or magnetic resonance imaging 
(MRI), ultrasonography can register movements and is therefore suitable to detect 
muscle movements such as fasciculations. Indeed, ultrasound seems to be more 
sensitive in detecting fasciculations when compared to needle EMG.18
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To determine its possible diagnostic utility in ALS, we assessed whether quantitative 
muscle ultrasonography can detect structural muscle changes in an early phase of the 
disease. We performed bilateral ultrasound measurements of five muscle groups in 
48 patients with ALS in the diagnostic stage.
METHODS 
Patients
We included 75 patients suspected of having ALS who were referred to our neuro muscular 
clinic between August 2003 and December 2005. All patients underwent a regular 
diagnostic workup consisting of at least a standard EMG examination and laboratory 
testing. When necessary, we excluded other diseases with additional diagnostic tests 
such as MRI or muscle biopsy. To assess the value of muscle ultrasound in detecting 
early disease-related changes, all ultrasound measurements were performed during the 
diagnostic process, i.e. before a final diagnosis was reached. After the inclusion was 
closed, medical records were reviewed to select patients who were diagnosed with ALS 
after a mean follow-up of 12 months. The final diagnosis was established by a clinical 
expert (H.J.S.) and classified using the revised El Escorial criteria.3 The local ethical 
committee approved the study, and all patients and volunteers gave informed consent.
Ultrasound measurements 
All ultrasound examinations were performed by three experienced clinical neuro-
physiology technicians, all of whom received a specific training for this purpose. All 
measurements were done using a phased-array real-time scanner with a 7.5-MHz 
transducer (Sonos 2000 Phased Array Imaging System; Hewlett-Packard, Andover, MA, 
USA). Equipment settings including gain (86 dB), compression (70 dB) and time-gain 
compensation were identical with our previous studies and based initially on a pilot study 
including healthy volunteers and a number of patients with neuromuscular disorders.14, 19 
All equipment settings were kept constant; only the depth setting was allowed to change 
during examination in order to display the entire muscle. The raw (analog) video signal 
was fed directly into a computer using a video grabber card (Meteor/RGB 571-0201; 
Matrox Electronic Systems Ltd., Dorval, Canada). The resulting bitmaps had a resolution 
of 800 × 600 pixels with 256 gray levels and were stored as tagged image file format 
files.
Ultrasound scans were made of the following muscles or muscle groups on both sides: 
sternocleidomastoid (bulbar), biceps brachii including the underlying brachialis muscle 
(cervical), forearm flexors (cervical), quadriceps femoris (lumbosacral) and the tibialis 
anterior muscle (lumbosacral).  
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The patient was placed in a supine position, with the arms and legs extended and the 
muscles relaxed. A generous amount of contact gel was used to minimize the required 
pressure of the transducer on the skin. All scans were made in the transverse plane 
with a standard transducer location corresponding to the muscle belly, at the following 
anatomical sites. The sternocleidomastoid muscle was measured halfway along the 
line from the mastoid bone to the cranial sternal margin, the biceps brachii muscle was 
measured at two-thirds the distance from the acromion to the antecubital crease, the 
forearm flexors were measured at two-fifths the distance from the antecubital crease 
to the distal end of the radius, the quadriceps femoris muscles were measured half-
way along the line from the anterior superior iliac spine to the superior aspect of the 
patella and the tibialis anterior muscle was measured at one-quarter the distance from the 
inferior aspect of the patella to the lateral malleolus.
For each muscle three consecutive measurements were taken to minimize variation in echo 
intensity. Oblique scanning can lead to incorrect muscle thickness and echo intensity and was 
avoided by adjusting the angle of measurement until the best bone echo was obtained. 
Measurement of muscle thickness
Muscle thickness was measured with electronic callipers placed at the following 
standardized locations: the thickness of the sternocleidomastoid muscle was measured 
between the upper boundary of its dorsal fascia and the lower boundary of its ventral 
fascia, the biceps brachii muscle between the upper margin of the humerus and the lower 
boundary of the ventral fascia of the biceps (including the underlying brachialis muscle), 
the forearm flexors between the interosseous membrane (next to the radius) and the 
lower boundary of the ventral fascia of the most ventral flexors, the quadriceps femoris 
between the upper margin of the femoral bone and the lower boundary of the ventral 
fascia of the rectus femoris (so including the rectus femoris and vastus intermedius) and 
the tibialis anterior between the interosseous membrane (next to the tibia) and the lower 
boundary of the ventral fascia of the tibialis anterior.
Measurement of echo intensity
Echo intensity was determined with computer-assisted gray-scale analysis using the 
standard histogram function in Adobe Photoshop 7.0 (Adobe Systems Inc., San Jose, 
CA, USA). A region-of-interest was selected in each muscle to include as much of the 
muscle as possible without any bone or surrounding fascia. The mean echo intensity 
of this region was calculated (resolution: 8 bit, black = 0, white = 255) and averaged 
over the three measurements per muscle. In the upper arm, only the biceps brachii was 
included for echo intensity measurements. In the quadriceps femoris, the rectus femoris 
muscle was used for analysis, because the outlines of the vastus intermedius muscle can 
be difficult to define in neuromuscular disorders.
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Muscle fasciculations
In 25 patients, each examined muscle was also screened for fasciculations. Each muscle 
was screened for 10 seconds, according to preciously published protocols.18 Muscle 
movements were classified as fasciculations if they appeared as involuntary twitching of 
small parts of the muscle for at least two times. They could be distinguished easily from 
other movements like arterial pulsations (unifocal, rhythmic) or voluntary movements 
(involving the entire muscle).20-22
Analysis
Data were analyzed using SPSS for Windows 12.0.1 (SPSS Inc., Chicago, Illinois, USA). 
Muscle thickness and echo intensity are different for each muscle group, and depend 
on age and gender.23 To compare individual patients and muscles, muscle thickness 
and echo intensity were transformed into z-scores.19, 24 For this, we used a previously 
established database to calculate normal values corrected for gender and age.23 This 
database contains 194 volunteers, including 103 males. The age ranged from 2 months 
to 90 years, with at least six men and women per decade.23 All subjects were healthy. 
We specifically assessed the absence of any neurological/neuromuscular disorders, 
diabetes mellitus and a family history for neurological disorders. The thickness of the 
biceps brachii muscles and the forearm flexors were also corrected for handedness. 
In effect, the z-score reflects the number of standard deviations a measure deviates 
from normal, given a certain age and gender. Comparisons were made using descriptive 
statistics. Standardized echo intensity and muscle thickness values were compared with 
normal using a one-sample t-test. Statistical significance was defined as a p-value ≤ 0.05.
RESULTS
Of the 75 patients included, 48 patients received a final diagnosis of ALS and were further 
analyzed (Table 1). All patients fulfilled the El Escorial criteria for (laboratory-supported) 
probable or definite ALS. The mean age was 64.1 ± 12.1 years. The average time from 
onset of symptoms to final diagnosis was 14 ± 12 months.
TABLE 1 Demographic characteristics 
Number 48
Sex (female / male) 26/22
Age (range) 64.1 (20.6 – 81.7) years
Length (range) 172 (146 – 190) cm
Weight (range) 73.7 (41.0 – 107.0) kg
Time since first symptoms (range) 14 (4 – 61) months
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Echo intensity and muscle thickness
In figure 1, representative ultrasound images of a 72-year-old female patient with ALS 
are shown with images of a healthy female of the same age selected from our normal 
database. In the patient with ALS, muscle thickness was clearly diminished in all muscles, 
except for the tibialis anterior. In all muscle groups, echo intensity was increased.  
FIGURE 1
Muscle ultrasound scans. Left colum 72 years old healthy female. Right colum 72 years old female 
patient with ALS, presenting with bulbair complaints and general muscle weakness since ten months. 
A: sternocleidomastoid muscle; B: biceps brachii muscle; C: forearm flexors; D: rectus femoris muscle; 
E: tibialis anterior muscle.
Z-scores echo intensity (EI) and muscle thickness (MT) of the ALS patient are shown in right corner of 
each scan. 
  
Echo intensity and muscle thickness were standardized using z-scores (see Methods). 
In table 2, mean z-scores over the whole ALS group are given. Echo intensity was 
significantly increased from normal, with a mean z-score ≥ 1 in each muscle group. The 
forearm flexors were most affected, with a mean z-score of more than 2 on both sides. 
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TABLE 2 Mean standardized echo intensity and muscle thickness (z-score) of patients  
 with ALS
Muscle thickness P-value  Echo intensity P-value
Sternocleidomastoid L -0.41 (-3.43 – 2.43) 0.037 1.27 (-1.22 – 7.00) <0.001
R -0.31 (-3.62 – 2.99) 0.137 1.23 (-1.20 – 7.55) <0.001
Biceps brachii L -1.37 (-4.84 – 1.97) <0.001 1.27 (-2.64 – 4.05) <0.001
R -1.31 (-6.52 – 1.86) <0.001 1.40 (-1.04 – 3.98) <0.001
Forearm flexors L -1.34 (-4.05 – 1.58) <0.001 2.32 (-1.41 – 5.99) <0.001
R -0.75 (-3.91 – 2.18) <0.001 2.19 (-0.60 – 6.60) <0.001
Quadriceps femoris L -1.03 (-4.91 – 1.72) <0.001 0.98 (-1.75 – 5.57) <0.001
R -1.05 (-4.53 – 2.15) <0.001 1.16 (-1.68 – 5.67) <0.001
Tibialis anterior L -0.14 (-3.30 – 2.13) 0.469 1.04 (-2.17 – 3.62) <0.001
R -0.18 (-3.64 – 1.79) 0.320 1.08 (-1.04 – 4.42) <0.001
Abbreviations used: L: left, R: right
Although there were significant decreases in muscle thickness in several groups, these 
were not as striking as the changes in echo intensity. Muscle thickness was decreased in 
the biceps brachii, forearm flexors and quadriceps muscles on both sides, with a mean 
z-score ranging between –0.75 and –1.37. In the bulbar region, only the left sternocleido-
mastoid reached significance and the tibialis anterior muscles were not significantly 
different from normal.
When muscle thickness and echo intensity were analyzed per region by summing 
z-scores of individual muscles, the overall findings remained the same (figure 2). Atrophy 
and an increase in echo intensity were most pronounced in the cervical region.
Muscle fasciculations 
Fasciculations were identified readily and detectable in all but one of the 25 patients 
screened. The mean number of muscles showing fasciculations was 6.5 (range 0 – 10, 
figure 3). Two patients showed clear fasciculations in all 10 scanned muscles. The one 
patient without fasciculations on ultrasound screening was also negative on clinical 
examination as well as electromyographical studies. 
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FIGURE 2
Histograms of composite z-score of the bulbar, cervical and lumbosacral region (analogue to the clinical 
El Escorial criteria). The mean composite muscle thickness for each region is shown in the left upper 
corner, the mean composite echo intensity in the right upper corner. Dotted lines represent a composite 
z-score of zero. Continuous lines represent the mean.
  
FIGURE 3
Histogram of number of muscles with fasciculations. The dotted line represents the mean.
  
70 Ultrasound abnormalities in ALS  Ultrasound abnormalities in ALS 
DISCUSSION
We show that muscle ultrasonography can detect muscle changes in the early stages 
of ALS. Quantitative analysis revealed an increase in echo intensity and decrease in the 
thickness of several muscles. The forearm flexors were most affected with mean z-scores 
of more than 2. These results striking given the fact that ALS is a patchy disease 1, 25; 
therefore, the average results per muscle group also included a number of normal 
muscles.  
Echo intensity can be judged visually, e.g. using the grading scale developed by 
Heckmatt et al.12 However, although this method is fast, the results are largely dependent 
on the experience and judgement of the examinator and the settings of the ultrasound 
machine. We therefore used quantitative computer-assisted grey-scale analysis in this 
study which is a more objective and accurate method.15 Moreover, quantitative grey-scale 
analysis has a higher interobserver agreement and a higher sensitivity compared with 
visual analysis. Finally, it allows easy statistical analysis, also on the group level. 
Our results imply that muscle ultrasonography may play a role in the diagnosis of ALS. 
Ultrasound examination yielded clear muscle changes in ALS. More importantly, these 
changes were already present in an early phase of the disease. All our subjects were 
scanned in the clinical diagnostic trajectory before conventional methods had resulted 
in a diagnosis. Although diagnostic tests often are more sensitive in patients who have 
a longer disease duration or who are more severely affected26, 27, ultrasonography is 
already sensitive in patients with a relatively short disease duration.
The next important aspect of a diagnostic test is the ability to differentiate between 
the target disorder and other diseases. The current study aimed to analyse ultrasound 
findings in patients with ALS in an early phase. To do so, we included patients in the 
diagnostic phase and therefore also patients suspected of having ALS who were ulti-
mately diagnosed with another disorder, i.e. an ‘ALS-mimic’. However, the ALS-mimic 
group was too small and too heterogeneous to allow proper statistical analysis on the 
specificity of muscle ultrasonography. Future studies using a prospective and blinded 
design according to the STARD criteria 28 are needed to establish the true diagnostic 
value of ultrasound examination.
In contrast to other imaging modalities, ultrasonography makes it possible to visualize 
dynamic aspects such as fasciculations, which are a prominent clinical feature of ALS. 
Indeed, fasciculations were easily identified in multiple muscles of all but one of our 
patients. The one patient without fasciculations on ultrasound was also negative on 
clinical and EMG screening. It is known that the absence of fasciculations does not 
Ultrasound abnormalities in ALS  71Ultrasound abnormalities in ALS 
preclude a diagnosis of ALS.3, 29 However, if present they form an important diagnostic 
clue. Fasciculations are regarded as a sign of lower MN degeneration and can be present 
before muscle weakness occurs.30, 31 Signs of upper and lower MN involvement in 
clinically unaffected regions are used to strengthen the clinical diagnosis of ALS in 
patients with limited disease presentation. To demonstrate subclinical lower MN 
involvement, patients are currently screened for fasciculations using needle EMG. 
Previous studies have already shown that ultrasonography is more sensitive than needle 
EMG in detecting fasciculations.18, 20-22 Together with our results, the available data 
suggest that fasciculation screening with ultrasound may be a useful and non-invasive 
addition to the diagnostic work-up.
There are only few studies using imaging techniques to describe muscle changes in ALS. 
Various studies used ultrasonography in a variety of neuropathic diseases, but none of 
them specifically described ALS related muscle changes.13, 32, 33 Overall, an increased 
echo intensity and decreased muscle thickness were the most common findings. In 
addition, Maurits et al. used texture analysis to quantify inhomogeneity in echo intensity, 
and found that to be the most pathological finding in neuropathic diseases.13 This is 
consistent with our findings in ALS, where the abnormalities in echo intensity were more 
striking than the decrease in muscle thickness. Others used MRI to study muscle changes 
in small groups of ALS patients.34 Although at baseline no evident atrophy was found, 
there were increases in T2 relaxation time which were attributed to fatty degeneration of 
muscle due to denervation. 
Although atrophy is a clinical hallmark of ALS, we show that echo intensity is more 
abnormal than muscle thickness. A possible explanation of this apparently contradictory 
finding may be that compensatory reinnervation may temporarily preserve muscle size, 
although the denervating process has already resulted in an increased echo intensity. 
The increased echo intensity is thought to be the result of altered muscle architecture and 
fatty and fibrous infiltration of the muscle.35 Histopathologically denervation is accompanied 
by muscle fiber atrophy, fiber necrosis and fibrosis.36, 37 When disease progression is not 
too fast, adequate reinnervation due to collateral sprouting from still unaffected nerve 
fibers38 may prevent muscle wasting and weakness. At least 30% of motor nerve fibers 
must be destroyed before the muscle shows any clinical sign of atrophy.37 Assessment of 
echo intensity can therefore probably be used to detect subclinically affected regions.
Muscle ultrasonography may also be useful in the monitoring of disease progression 
in ALS. Objective monitoring of disease progression is especially important in 
studies evaluating therapeutic interventions. Guidelines for the use and performance of 
quantitative outcome measures in ALS clinical trials are developed by the World 
Federation of Neurology.39 These include respiratory function tests, muscle strength and 
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bulbar function tests, but all these tests are hindered by the fact that muscle reinnervation 
can masquerade real disease progression. Although muscle thickness measured by 
ultrasound is also hampered by this, echo intensity is probably not. In addition, the data 
on muscle thickness provided by muscle ultrasound may be more sensitive to minor 
changes when compared to manual muscle testing or maximum voluntary isometric 
contraction measurements. Clearly, it is more objective and far less exhausting for the 
patient.
Conclusion
We established that muscle abnormalities due to ALS can be detected and quantified 
with muscle ultrasound. In addition, our findings suggest that preclinical signs of 
denervation such as fasciculations and an increase in fibrous tissue, can be detected by 
ultrasound and be used to increase diagnostic certainty. Further studies are necessary 
to examine the diagnostic test characteristics of muscle ultrasonography in ALS and the 
ability to monitor disease progression. 
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Ultrasound is a rapidly evolving technique that can be used in the diagnostic work-up of 
neuromuscular disorders.1 Affected muscles show a diminished muscle thickness and 
an increased echo intensity.2-4 Previous studies have found that fat and fibrous tissue 
each can increase echo intensity. However, the exact cause of increased echo intensity 
is not fully known.2, 5, 6   
We compared the findings of an in vivo quantitative muscle ultrasound study with the 
post-mortem histopathological examination of a 62-year-old female with amyotrophic 
lateral sclerosis (ALS). This patient died 27 months after symptom onset. On autopsy, the 
diagnosis ALS was confirmed. 
Transverse ultrasound scans and total cross sectional muscle specimens of nine 
different muscles were taken from the same standardized anatomical sites (Figure 1).7 
Autopsy was performed with informed consent of the patient, within 12 hours after death. 
Muscle specimens were fixed in 4% formalin; the fibers were orientated transversely for 
embedding in paraffin. The largest cross-sectional area of each sample was selected and 
cut in 4 μm thick sections which were stained with Masson trichrome. The percentage 
perimysial and endomysial tissue and the percentage of interstitial fat were determined 
by digital image analysis.8
The ultrasonography examinations were performed 3 months before death. Details of the 
standardized protocol and system settings have been described elsewhere.7 
Echo intensity was determined quantitatively using histogram analysis, in which the 
mean grey value of the muscle is expressed as a value between 0 (=black) and 255 
(= white).7 
Echo intensity was increased in all muscles (mean 73; range 52-91), to about twice the 
normal value.7 
Histological examination showed a comparable percentage of intramuscular fat (median 
8.6%; range 4.9-16.2%) and fibrous tissue (12.5%; range 6.7-28.5%, figure 1D). Fibrous 
tissue seemed to be more evenly distributed within the muscle, while fat was located in 
small collections (Figure IC). The sternocleidomastoid muscle was considered an outlier 
and was not used for calculation of correlations. Echo intensity was strongly correlated 
with fibrous tissue (r = 0.86, p = 0.007; figure 1D) and this correlation remained after 
correction for fat content (r = 0.81, p = 0.026). Echo intensity and the amount of fatty 
tissue were not correlated (r = -0.46, p = 0.248), also not after correction for fibrous 
tissue (r = -0.07, p = 0.886). 
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FIGURE 1
An example of an ultrasonography scan (A), graphical representation of the scan (B) and muscle histo-
pathology (C) of the biceps brachii. A Masson trichome staining was applied to the muscle specimen. 
In this black and white image the perimysial tissue is light grey, whereas muscle tissue is dark grey. Fat 
(not coloured with this staining) was less evenly distributed within the muscle compared to fibrous tissue 
(arrows). Panel D shows the correlation of muscle echo intensity and the percentage of fibrous tissue. 
Panel E and F illustrate the association between echo intensity and fat and between fat and fibrous 
tissue. The numbered markers represent the following muscles: 1 right biceps; 2 left biceps; 3 right 
forearm flexor group; 4 left forearm flexor group; 5 right quadriceps; 6 left quadriceps; 7 right tibialis 
anterior; 8 left tibialis anterior; 9 left sternocleidomastoid muscle. This latter muscle was considered an 
outlier and was not used for calculation of correlation. 
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In both our current study of a human neurogenic disorder as in a previous study of 
canine muscular dystrophy, fibrous tissue was the main contributing factor to increase 
muscle echo intensity.5 However, other studies have indicated that intramuscular fat also 
contributes to increased echo intensity, as shown in patients with little or no fibrous 
tissue2, 6 and in obese people.9 In our present study the amounts of fibrous and fatty 
tissue were comparable, making it possible to study the influence of both variables on 
echo intensity simultaneously. The influence of fibrous tissue on echo intensity appeared 
to be stronger than that of fat, which might be caused by differences in their distribution 
within the muscle. Overall this suggests that fibrosis is the most important determinant of 
muscle echo intensity in ALS.
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ABSTRACT
In a prospective study we tested whether muscle ultrasonography can differentiate 
between amyotrophic lateral sclerosis (ALS) and mimics. Furthermore, we assessed 
the ability of ultrasonography to identify subclinical lower motor neuron involvement. In 
59 patients, suspected for adult onset motor neuron disease, ultrasound scans were 
made of 12 different muscle groups. Echo intensity was determined and each muscle 
was screened for fasciculations. Ultrasonography was considered diagnostic for ALS 
when echo intensity was 1.5 SD above normal in at least 2 muscles and fasciculations 
were present in at least 4 muscles. Ultrasonography differentiated between ALS and 
mimics with 96% sensitivity and 84% specificity. In the 27 ALS patients, ultrasonography 
detected 15 regions with lower motor neuron involvement that were negative using either 
clinical examination or needle EMG. We conclude that muscle ultrasound can differentiate 
between amyotrophic lateral sclerosis and mimics with high sensitivity and specificity, 
and is a sensitive tool to screen for regional lower motor neuron involvement.
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INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a fatal disease, caused by degeneration of both 
upper and lower motor neurons (MN). The disease course is characterized by progressive 
weakness and muscle atrophy, leading to disability and eventually death with a median 
survival of 28 months from symptom onset.1 Due to a heterogeneous disease presen-
tation and lack of a diagnostic marker, the diagnosis ALS can be difficult to make. The 
number of misdiagnoses is high with a false-negative rate of approxi mately 40% 2, 3 and 
a false-positive diagnosis in about 8%.4 Moreover, the median interval between symptom 
onset and ALS diagnosis is equal to one third of the life expectancy of patients.1, 5
ALS is part of the spectrum of motor neuron diseases (MND). This spectrum ranges 
from diseases with isolated lower MN involvement like progressive muscular atrophy to 
disorders with isolated upper MN involvement like primary lateral sclerosis. The diagnosis 
ALS is considered when signs of both lower and upper MN involvement are found 
combined with a progressive disease course. Other diseases can present with similar 
symptoms or signs, and these so called “ALS-mimics” have to be excluded. Well-known 
mimics are (myelo)radiculopathy, multifocal motor neuropathy, benign cramp fasciculation 
syndrome, Kennedy’s disease and myopathies.6 
In the absence of a solid diagnostic biomarker, diagnostic certainty is expressed in levels 
of probability. In effect, a higher level of diagnostic certainty is reached if more body 
regions reveal combined upper and lower MN involvement. The most commonly used 
diagnostic standards are the revised El Escorial criteria.7 Based on clinical findings and 
electromyography (EMG) examination, diagnostic certainty is expressed in four levels 
(figure 1). The categories “possible”, “probable” and “definite” ALS are defined on 
clinical grounds alone. A special diagnostic category is “probable laboratory supported 
ALS”. In this category, EMG findings are used to detect subclinical lower MN involvement 
in order to increase diagnostic certainty.
Muscle ultrasonography may be a useful tool to improve the diagnostic work-up in ALS. 
Previously, we showed that ultrasonography can detect structural muscle changes in an 
early phase of ALS. Affected muscles revealed a diminished muscle thickness, increased 
echo intensity and fasciculations.8 Echo intensity is the result of reflection of ultrasound 
waves when the ultrasound beam encounters a tissue with different acoustical properties. 
Increased intramuscular fibrous and fatty tissue, for example due to denervation, gives 
a larger number of layers with different acoustical properties and therefore a higher 
echo intensity. As denervation already takes place before muscles become paretic,9, 10 
increased echo intensity, atrophy and fasciculations can be found in muscles with 
preserved strength.11 
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FIGURE 1
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Probable ALS  
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supported
Probable ALS Definite ALS
Flowdiagram representing the revised El Escorial criteria.
In the el Escorial criteria 4 different body regions are acknowledged: bulbar, cervical, thoracic and 
lumbosacral. Signs of upper MN degeneration: spastic tone, preserved reflex in weak wasted limb, 
and/or pathological reflexes. Signs of lower MN involvement: weakness, atrophy and/or fasciculations. 
Electromyographic lower MN involvement: a combination of chronic (large or unstable motor unit 
potentials and reduced interference pattern) and active denervation (fibrillation potentials or positive 
sharp waves). These EMG abnormalities are required in one muscle for the bulbar and thoracic region 
and in two muscles for the cervical and lumbosacral region.
In this study, we prospectively evaluated the diagnostic accuracy of muscle ultrasound 
in the work-up of patients with suspected ALS. In a second analysis, the sensitivity of 
muscle ultrasound for the detection of regional lower MN involvement was compared 
with both clinical evaluation and EMG. 
METHODS 
General layout of the study
This prospective and blinded study was performed according to the Standards for 
Reporting of Diagnostic Accuracy (STARD) and consists of two parts (figure 2). In part 1 
of the study the diagnostic accuracy of ultrasound was established. For this, we used 
the El Escorial criteria as reference standard (“gold standard”). Details of the study 
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are reported in the STARD checklist (see Supplementary Data). In part 2, the sensitivity 
of ultrasonography for detecting regional lower MN involvement was determined and 
compared with clinical evaluation and EMG. 
FIGURE 2 Flowchart illustrating the study design
PART 1 Patients suspected for adult onset MND
Reference diagnosis 
Based on revised El 
Escorial criteria, using:
Clinical examination
EMG
Nerve conduction studies
Follow up 12 months
Additional test
+
Ultrasonography
Requirement positive test:
Echo intensity ≥ 1.5 in ≥ 2 
muscles and fasciculations 
in ≥ 4 muscles 
Reference diagnosis: 
ALS/PMA
AND
Ultrasonography 
positive
Reference diagnosis: 
ALS/PMA
AND
Ultrasonography 
negative
Reference diagnosis: 
control
AND
Ultrasonography 
positive
Reference diagnosis: 
control
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Ultrasonography 
negative
PART 2 Patients with ALS
Regional lower motor neuron involvement
Clinical 
Weakness
Atrophy
Fasciculations 
EMG
Chonic + active 
denervation
Bulbar and thoracic 
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Cervical and  
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Ultrasonography
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Bulbar and thoracic 
region: 1 out of 2 
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Cervical and  
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Subjects 
All consecutive patients that visited our tertiary MND clinic between March 2008 and 
March 2009 were included for the study. Inclusion criteria were: patient with suspected 
adult onset MND, aged between 18 and 85 years. The study was approved by the local 
ethics committee and informed consent was obtained from all participants prior to inclusion. 
Clinical evaluation
The clinical work-up included: clinical examination, nerve conduction studies, EMG and a 
follow up of at least 12 months. All EMGs were performed or supervised by an experienced 
clinical neurophysiologist, blinded for the ultrasound results. The number of muscles 
that were examined by needle EMG was dependent on the extent of clinical doubt at 
presentation, and thus varied between patients. On average, 3 regions (range 2-4) and 
6 muscles (range 2-17) were examined. When necessary, other diseases were excluded 
with additional diagnostic tests such as laboratory testing, MRI or muscle biopsy.
Ultrasonography 
The neurological examination, EMG, and muscle ultrasound were performed before 
the diagnosis was established and all on the same day. Ultrasound scans were made 
by experienced clinical neurophysiology technicians, blinded for the suspected clinical 
diagnosis. We used a standardized protocol that was described previously.8, 12 The muscles 
that were examined with corresponding transducer location are presented in Table 1. 
Transverse ultrasound scans were made of all muscles on both sides. Measurements 
were performed using a Philips IU22 with a 5-17 MHz linear broadband transducer. 
TABLE 1  Examined muscle (groups) with corresponding transducer location and caliper position 
Assessment of echo intensity and presence of fasciculations
Transducer location
SCM ½ distance mastoid bone – cranial sternal margin
Biceps brachii ⅔ distance acromion – antecubital crease
Forearm flexors ⅖ distance antecubital crease – distal end radius
Quadriceps femoris ½ distance anterior superior iliac spine – superior aspect patella
Tibialis anterior ¼ distance inferior aspect patella – lateral malleolus
Fasciculation screening only
Transducer location
Rectus abdominis 2 cm cranial from the umbilicus
SCM; sternocleidomastoid
The rectus abdominis was only screened for the presence of fasciculations, since there were no normal values for echo 
intensity at that time.
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Measurement of echo intensity 
For the calculation of echo intensity, the ultrasound images were stored for further offline 
evaluation. In each muscle image a region of interest was selected including as much of 
the muscle as possible without any bone or surrounding tissue. The mean echo intensity 
of this region was calculated and averaged over the three measurements per muscle. 
Echo intensity was corrected for age, gender and handedness and transformed into 
z-scores,12 reflecting the number of standard deviations a measure differs from the 
average value in normal subjects.
Muscle fasciculations 
For each muscle a 10 second movie was recorded and stored for further evaluation 
offline. Each movie was reviewed for the presence of fasciculations by an experienced 
investigator (I.A.), blinded for the reference diagnosis. Movements were classified as 
fasciculations if they appeared as twitching of small parts of the muscle for at least two 
times.13, 14 
Part 1. Diagnostic accuracy of muscle ultrasound in detecting ALS
Reference standard 
The revised El Escorial criteria, including follow up of at least one year, was used as the 
reference standard for ALS. The ultimate diagnosis was made by a clinical expert (H.J.S.) 
blinded for the ultrasound results. Patients were classified as ‘ALS’ (including patients 
with progressive muscular atrophy) or as ‘control’ (i.e. all referred patients who did not 
receive an ALS diagnosis). 
Ultrasonography 
Prior to analysis, a cut-off point for an abnormal ultrasound measurement (i.e. diagnostic 
for ALS) was determined, based on a pilot study describing ultrasound abnormalities 
in 48 ALS patients and 27 patients with a mimic.8 This cut-off point was set at an echo 
intensity above 1.5 SD (z-score) in at least two, and fasciculations in four out of ten 
muscles (irrespective of regions). This cut-off point reached a sensitivity of 83% and a 
specificity of 91% in the pilot study. Although atrophy is a classic clinical feature of ALS, 
adding muscle thickness to the cut-off criterion did not lead to better accuracy and for 
this was not included in the cut-off value. 
Analysis
Data were analyzed using SPSS for Windows 16.0 (SPSS Inc., Chicago, IL, USA). 
A power analysis based on our pilot study,8 showed that inclusion of at least 48 patients 
was necessary to detect a difference of 4 muscles with fasciculations between ALS and 
the control group with 90% power (α 0.05). 
The described cut-off point was applied to all muscle ultrasound measurements and 
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compared to the final diagnosis. Specificity, sensitivity and positive and negative 
likelihood ratio were determined. The 95% confidence intervals (CI) for proportions were 
calculated using the efficient-score method with correction for continuity.15 
Part 2 Detection of regional lower MN involvement
In the patients with ALS, ultrasonographic findings were compared to EMG and clinical 
examination. Regions with missing clinical, EMG or ultrasound data were excluded. The 
same analysis was done for each body region separately. Furthermore, we assessed the 
number of regions with ultrasonographic lower MN involvement for each ALS patient.
Regional lower MN involvement was defined as:
• Clinical: weakness, atrophy or fasciculations.7
• EMG: The revised El Escorial criteria for electromyographic regional lower MN involve-
ment, being a combination of active and chronic denervation were used.7 For a region 
to be involved, EMG abnormalities had to be present in at least one muscle for the 
bulbar and thoracic region and in at least two muscles for the cervical and lumbosacral 
regions. 
• Ultrasonography: Regional lower MN involvement was based solely on the presence of 
fasciculations; adding echo intensity or atrophy as additional features did not lead to 
better specificity, but diminished the sensitivity in the pilot study.8 The required number 
of muscles with fasciculations within each region was: bulbar and thoracic region 
fasciculations in at least one of the two measured muscles, for the cervical and lumbo-
sacral region fasciculations in at least two of the four measured muscles. 
To determine whether fasciculation screening alone, without concomitant echo intensity 
analysis would decrease the specificity of ultrasound we evaluated the presence of more 
than 3 regions with ultrasonographic lower MN involvement in the control group.
RESULTS
Over the inclusion period, 59 eligible patients were recruited. Twenty-seven patients 
(70% males) were diagnosed with ALS and 32 (74% males) were classified as control 
(Figure 3). The median age of the ALS group was 62 years (range 23-79) with a disease 
duration from symptom onset of 10 months (2-40). For the control group the median age 
was 56 years (29-80), with a disease duration of 13 months (1-456). 
Part 1 Diagnostic accuracy of muscle ultrasound in detecting ALS
Ultrasonography was able to differentiate between patients with and without ALS with 
a sensitivity of 96.3% (95% CI 79.1-99.8%) and a specificity of 84.4% (66.5-94.1%), 
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resulting in a positive likelihood ratio of 6.17 (2.7-13.8) and negative likelihood ratio of 
0.04 (0.01-0.25). 
The false positive ultrasound studies (n = 5) concerned a 67-year-old male, with 
sensomotor axonal polyneuropathy and fasciculations due to thyroidal dysregulation; 
a 59-year-old male with polyradiculopathy due to degenerative alterations of the spine; 
a 79-year-old female with mononeuropathia multiplex; a 72-year-old male with senso-
motor axonal polyneuropathy and beta sympathicomimetics induced fasciculations; and 
a 36-year-old male with benign cramp- fasciculation syndrome. The false negative patient 
(n = 1) was a 79-year-old male with probable ALS, presenting with bulbar complaints 
one year before the diagnosis. A detailed description of these patients is presented as 
additional data (Supplementary Data).
FIGURE 3 Flowdiagram summarizing the inclusion of patients in the study.
Patients suspected for adult onset MND
N = 59
Reference test + Ultrasonography
Reference 
diagnosis:  
ALS/PMA
AND
Ultrasonography 
positive
n = 26
Reference 
diagnosis:  
ALS/PMA
AND
Ultrasonography 
negative
n = 1
Reference 
diagnosis: 
control
AND
Ultrasonography 
positive
n = 5
Reference 
diagnosis: 
control
AND
Ultrasonography 
negative
n = 27
Possible ALS n = 7
Prob. lab. sup. ALS n = 6
Probable ALS n = 9
Definite ALS n = 1
PMA n = 3
Probable ALS n = 1 PNP + fasc.  
metabolic n = 1
PNP + fasc toxic n = 1
Benign cramp fasc. n = 1
Polyradiculopathy n = 1
MNM n = 1
Polyradiculopathy n = 5
HSP/PLS n = 6
Myopathy n = 5
Benign cramp fasc. n = 3
PSP n = 1
Plexopathy n = 2
No neurology n = 3
Cerebral vasc. n = 1
Abbreviations used: prob. lab. sup.; probable laboratory supported ALS, PMA; progressive muscular 
atrophy, PNP; polyneuropathy, fasc.; fasciculations, MNM; mononeuropathia multiplex, HSP; hereditary 
spastic paresis, PLS; primary lateral sclerosis, benign cramp fasc; benign cramp fasciculation syndrome, 
PSP; progressive supranuclear palsy, cerebral vasc; cerebral vascular lesions.
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Part 2 Detection of regional lower MN involvement
In the ALS patients, clinical, EMG, and ultrasound data of 89 regions (20 bulbar, 27 cervical, 
15 thoracic, 27 lumbosacral) were available for further analysis.
Using the described measurement protocol, ultrasonography was more sensitive in 
detection of regional lower MN involvement than EMG. Signs of lower MN involvement 
were found in 71 out of 89 regions (80%) using ultrasonography, in 61 regions (68%) 
with clinical examination and in 40 regions (45%) with EMG (Table 2). Ultrasonography 
showed signs of lower MN involvement in 15 of the 24 regions that were negative both 
clinically and with EMG. Conversely, EMG was positive in only one of the ten regions that 
were negative both clinically and using ultrasonography. Ultrasound was especially more 
sensitive compared to EMG in the bulbar and lumbosacral region (Table 2). 
TABLE 2  The number of regions with lower motor neuron involvement with clinical examination   
 compared to EMG and ultrasonography, for each body region separately. 
Clinically unaffected
regions
Clinical affected
regions
EMG + EMG - EMG + EMG -
Bulbar US  + 0 5 3 4
n = 20 US   - 0 3 0 5
Cervical US  + 0 1 20 5
n = 27 US   - 0 0 0 1
Thoracic US  + 1 3 2 1
n=15 US   - 1 5 1 1
Lumbosacral US  + 2 6 10 8
n=27 US   - 0 1 0 0
Total US  + 3 15 35 18
n = 89 US   - 1 9 1 7
In the ALS group, 16 patients showed lower MN involvement in 3 or more regions, 
including 5 out of 7 patient with possible ALS and all 6 patients with probable laboratory 
supported ALS. 
In the control group (n=32) only two patients showed ultrasonographic lower MN involve-
ment of 3 or more regions, giving a specificity of 94% (95% CI 78 - 99%). 
DISCUSSION
Ultrasonography can be used to discriminate between ALS and mimics with a high 
sensitivity and specificity. In addition, in patients with ALS ultrasonography is a highly 
sensitive tool to screen for regional lower MN involvement.
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The presented sensitivity and specificity are based on ultrasound finding only. Ultrasono-
graphy, like needle EMG, provides information concerning lower MN involvement while 
the diagnosis ALS also requires signs of upper MN and (near) normal nerve conduction 
studies7. All five false positive patients showed no upper MN signs and three of them had 
abnormal nerve conduction studies. Therefore, in clinical practice a higher specificity is 
feasible because ultrasound results are combined with clinical findings. 
Ultrasonography is a sensitive tool to assess subclinical regional lower MN dysfunction. 
Regional lower MN involvement was detected in more regions using ultrasonography as 
compared to EMG. A part of the difference in sensitivity between ultrasonography and 
EMG might be explained by dissimilarity in extensiveness of the examination. The sensitivity 
for EMG is dependent on the duration of screening of each muscle,16 the number of 
muscles studied17 and the method of analysis.18 We compared muscle ultrasound with 
EMG as performed in standard clinical care. Muscle ultrasound was routinely performed 
according to a standard protocol involving 12 muscles. In contrast, the number of 
muscles studied by needle examination was, consistent with standard clinical care, 
dependent on the extent of clinical doubts. The diagnostic accuracy of muscle ultrasound 
might be further improved by alteration of the required abnormal muscles per regions or by 
adding other muscles to the protocol. The sensitivity of detection of lower MN involvement 
with ultrasonography in those muscles should be further explored.
We used the presence of fasciculations as a criterion for ultrasonographic lower MN 
involvement. Despite the fact that fasciculations are a prominent feature of ALS, their 
diagnostic role in the revised El Escorial criteria is limited.7 The main motivation for this 
was never formally stated, but seems to be the concern for false positive diagnosis, since 
fasciculations are not ALS-specific.19 That this concern is not justified, became clear with 
the development of the Awaji criteria.20 These proposed new diagnostic ALS criteria, in 
which fasciculations have a more prominent diagnostic role, were established in order to 
increase sensitivity. Application of the Awaji criteria does not result in lower specificity.21, 22 
Our control group included a few patients in whom additional tests like EMG or ultra-
sonography were not strictly necessary to establish the diagnosis. However, in clinical 
practice, additional tests are often performed to exclude a devastating disease like ALS, 
even if this is strictly not required. Due to the prospective character of the study, our 
control group did not include some well-known ALS mimics. Therefore, additional studies 
to assess the ultrasound characteristics in mimics like Kennedy disease, multifocal motor 
neuropathy or chronic inflammatory demyelinating neuropathy, are warranted. 
Echo intensity is dependent on settings and used ultrasound device. For each device 
new normal values for echo intensity have to be established or existing normal values can 
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be used after application of a conversion procedure.12, 23 Measurement of echo intensity 
necessitates some degree of experience. With a standardized protocol it takes a few 
weeks to learn how to make reliable scans. By doing so interobserver agreement with 
a kappa coefficient of 0.86 can be obtained. The detection of fasciculations is straight-
forward, they are easy to recognize13, 14, 24 and normal values are provided.24
Conclusion
Muscle ultrasonography is a promising tool in the diagnostic work up of ALS. Especially 
the sensitivity to detect fasciculations is an important asset of ultrasonography and 
maybe used to increase diagnostic certainty. Although the gold standard to detect 
denervation will remain in the EMG domain, ultrasound might substitute part of the EMG 
protocol in the search for lower MN involvement; reducing the number of muscles that 
require needle examination.
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SUPPLEMENTARY 
SUPPLEMENTARY DATA 1. 
STARD checklist
1. Identify the article as a study of diagnostic accuracy (recommended MeSH heading 
“sensitivity and specificity”)
 This was done.
2. State the research questions or study aims, such as estimating diagnostic accuracy 
or comparing accuracy between test or across participant groups.
 First aim: establishing the diagnostic accuracy of muscle ultrasound in ALS 
 Second aim: comparing the sensitivity of ultrasonography to detect regional lower 
motor neuron involvement with clinical or EMG evaluation.
3. Describe the study population: The inclusion and exclusion criteria, setting and 
locations were the data were collected.
 Multicentre study performed at the outpatient MND clinic of the Radboud university 
medical centre, a tertiary referral center in the Netherlands. 
 Inclusion criteria: patient with suspected adult onset motor neuron disease, aged 
between 18 and 85 years. 
 Exclusion criteria: patients with severe cognitive impairment interfering with the ability 
to provide informed consent.
4. Describe patient recruitment: Was recruitment based on presenting symptoms, 
results from previous test, or the fact that the participants had received the index test 
or the reference standard?
 We recruited all patients that were referred to our centre with suspected adult onset 
motor neuron disease. Thus, recruitment was based on the clinical suspicion of the 
referring specialist.
5. Describe participant sampling: Was the study population a consecutive series of 
participants defined by the selection criteria in items 3 and 4? If not, specify how 
participants were further selected.
 Yes, the study population was a consecutive series of participants without further 
selection. 
6. Describe data collection: Was data collection planned before the index test and 
reference standard were performed (prospective study) or after (retrospective study)?
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 This is a prospective study, the data collection was planned before the index test and 
reference standard were performed.
7. Describe the reference standard and its rationale.
 At the start of this study, the revised El Escorial criteria were the most commonly used 
were therefore applied as the reference diagnostic system. 
8. Describe technical specifications of materials and methods involved including how 
and measures were taken, and/or cite references for index tests and reference 
standard.
 The work-up for the reference diagnosis included: clinical examination, EMG, nerve 
conduction studies and a follow up period of at least 12 months. When necessary 
additional diagnostic test such as laboratory testing, MRI or muscle biopsy were 
performed. 
 The ultrasound examination was performed using a Philips IU22 with a 5-17 MHz 
linear broadband transducer. A standardized protocol was used that was described 
previously (Arts et al, Ultrasound Med Biol 2008; Arts et al, Muscle Nerve 2010).
 Echo intensity
 For calculation of the echo intensity, the ultrasound images were stored for further 
offline evaluation. Using customized image analysis software that was developed at 
our department (Qumia, www.qumia.nl), a region of interest was selected in each 
muscle image. This region of interest included as much of the muscle as possible 
without any bone or surrounding tissue. The mean echo intensity of this region was 
calculated and averaged over the three measurements per muscle. Echo intensity 
were corrected for age, gender and handedness and transformed into z-scores, 
reflecting the number of standard deviations a measure differs from normal.
 Muscle fasciculations 
 Ultrasonography is a sensitive and reliable technique to detect fasciculations 
(Reimers et al. J. Neurol 1996) For each muscle a 10 second movie was recorded 
and stored for further evaluation offline. Each movie was reviewed for the presence of 
fasciculations by an experienced investigator (I.A.), blinded for the reference diagnosis. 
Movements were classified as fasciculations if they appeared as twitching of small 
parts of the muscle for at least two times. Fasciculations can be distinguished from 
other movements like arterial pulsations (unifocal, rhythmic) or voluntary movements 
(involving the entire muscle). (Reimers et al. J. Neurol. 1996; Wenzel et al .J. Neuro-
imaging 1998). 
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9. Describe definition of and rationale for the units, cutoffs and/or categories of the 
results of the index tests and the reference standard.
 Prior to analysis, a cut-off point for an abnormal ultrasound measurement (i.e. 
diagnostic for ALS) was determined, based on a pilot study describing ultrasound 
abnormalities in 48 ALS patients and 27 patients with a mimic (Arts et al. 2008). 
This cut-off point was set at echo intensity above 1.5 SD (z-score) in at least two out 
of ten muscles and fasciculations in four out of ten muscles (irrespective of regions). 
This cut-off point had resulted in the highest sensitivity (83%) and specificity (91%) in 
the pilot study.
10. Describe the number, training and expertise of the persons executing and reading 
the index tests and the reference standard.
 The reference diagnosis was established by one neurologist specialized in motor 
neuron diseases. The EMG examination that formed part of the reference standard 
were done or supervised by an experienced clinical neurophysiologist. 
 The ultrasound examination were done four experienced clinical neurophysiology 
technicians. Evaluation of the ultrasound movies on the presence of fasciculations 
was done by one experienced examiner (IA). 
11. Describe whether or not the reader of the index tests and reference standard 
were blind (masked) to the results of the other test and describe any other clinical 
information available to the readers.
 The neurologist that established the reference diagnosis and the EMG-ists were 
blinded for the ultrasound results. 
 The clinical neurophysiologist performing the ultrasound examination and the 
examiner that assessed the videos for the presence of fasciculations were blinded for 
the diagnosis and the EMG results. 
12. Describe methods for calculating or comparing measures of diagnostic accuracy, and 
the statistical methods used to quantify uncertainty (e.g. 95% confidence intervals).
 Specificity, sensitivity and positive and negative likelihood ratio were determined. The 
95% confidence intervals (CI) for proportions were calculated using the efficient-score 
method with correction for continuity (Newcombe Stat Med 1998)
13. Describe methods for calculating test reproducibility, if done.
 The interobserver agreement for quantitative echo intensity assessment (kappa coefficient 
of 0.86, Pillen et al. Muscle Nerve 2008) and fasciculation detection (kappa coefficient of 
0.82, Fermont et al. Amyotroph Lateral Scler 2010) were established previously.
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14. Report when study was done, including beginning and ending dates of recruitment.
 Inclusion took place between March 2008 and March 2009, to recruit at least 
48 patients. Power analysis based on our pilot study (Arts et al. Ultrasound Med Biol 
2008) showed that inclusion of at least 48 patients was necessary. This number of 
patients was required to detect a difference of 4 muscles with fasciculations (out of 
10 measured muscles) between ALS (including PMA) and the control group with 90% 
power (α 0.05). 
15. Report clinical and demographic characteristics of the study population (e.g. age, 
sec, spectrum of presenting symptoms, comorbidity, current treatments, recruitment 
centers).
 Twenty-seven patients (70% males) were diagnosed with ALS, the other patients were 
included in the control group (74% males). The median age of the ALS group was 
62 years (range 23-79) with a disease duration from symptom onset of 10 months 
(2-40). For the control group the median age was 56 years (29-80), with a disease 
duration of 13 months (1-456). 
16. Report the number of participants satisfying the criteria for inclusion that did or did 
not undergo the index tests and/or the reference standard; describe why participants 
failed to receive either test (a flow diagram is strongly recommended).
 All 59 included participants underwent the index and the reference standard.
17. Report time interval from the index tests to the reference standard, and any treatment 
administered between.
 The index test was performed on the same day as the test to form the reference 
standard (except for the follow up period of 12 months). No special treatment was 
started that day. 
18. Report distribution of severity of disease (define criteria) in those with the target 
condition; other diagnoses in participants without the target condition.
 The ALS group consisted of 3 patients with PMA and 7 patients with possible, 6 with 
laboratory supported probable, 10 with probable and 1 with definite ALS.
 The control group consisted of: 6 patients with polyradiculopathy, 6 with HSP/PLS, 
5 with a myopathy, 4 with benign cramp fasciculation syndrome, 2 with plexopathy, 
1 with polyneuropathy and metabolic induced fasciculations, 1 with polyneuropathy 
and toxic induced fasciculation, 1 with mononeuropathia multiplex, 1 with progressive 
supranuclear palsy, 1 with ischemic cerebral lesions and 3 without evident neurologic 
disease at moment of evaluation.
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19. Report a cross tabulation of the results of the index tests (including indeterminate 
and missing results) by the results of the reference standard; for continuous results, 
the distribution of the test results by the results of the reference standard.
 This is represented in the flowchart.
20. Report any adverse events from performing the index tests or the reference 
standard.
 There were no adverse events.
21. Report estimates of diagnostic accuracy and measures of statistical uncertainty (e.g. 
95% confidence intervals).
 We found a sensitivity of 96.3% (95% CI 79.1-99.8%), a specificity of 84.4% 
(66.5-94.1%), positive likelihood ratio of 6.17 (2.7-13.8) and negative likelihood ratio 
of 0.04 (0.01-0.25).
22. Report how indeterminate results, missing responses and outliers of the index tests 
were handled.
 There were no indeterminate results, missing responses or outliers.
23. Report estimates of variability of diagnostic accuracy between subgroups of 
participants, readers or centers, if done.
 This was not established in this study.
24. Report estimates of test reproducibility, if done.
 This was not done in this study.
25. Discuss the clinical applicability of the study findings.
 The clinical applicability is a described in the discussion. 
SUPPLEMENTARY DATA 2.  
Details of the false negative and the false positive patients. 
False negative 
The false negative ultrasound study of a 79-year-old male with probable ALS, showed 
fasciculations in almost all muscles, but echo intensity was not increased. This patient 
noticed bulbar problems a year before the diagnosis. At time of diagnosis signs of lower 
motor neuron (MN) loss were found in 2 regions and upper MN loss in 3 regions. Two 
regions fulfilled the needle electromyographic (EMG) criteria for lower MN loss according 
the el Escorial criteria. Approximately 14 months after symptom onset, the patient died 
due to respiratory dysfunction. On autopsy the diagnosis ALS was confirmed. 
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False positives
There were 5 false positive patients.
I. A 67-year-old male with a positive family history for ALS. One of his seven brother 
and sisters was diagnosed with ALS and died in 2005. This patient was ultimately 
diagnosed as sensomotor axonal polyneuropathy and fasciculations probably due 
to thyroidal dysregulation. He presented with fasciculations and cramps in arms and 
legs, but without pareses or signs of UMN pathology. Nerve conduction studies and 
needle EMG, revealed a severe sensomotor axonal polyneuropathy, with fibrillations 
and fasciculations in the anterior tibial muscle and fibrillations in the first interos-
seus dorsal muscle, but no signs of active denervation in the proximal muscles. 
Ultrasonography showed fasciculation in forearm flexors, quadriceps, tibialis and 
rectus abdominus muscles and a slightly increased echo intensity of the forearm 
flexors, sternocleidomastoid and tibialis muscle on one side. Repeated physical and 
electrophysiological studies after 6 months and telephonic inquiries after 4 years 
revealed no signs of transformation to ALS. 
II. A 59-year-old male with polyradiculopathy. This patient not only had a false positive 
ultrasound study, but electrophysiological studies were also suggestive for 
generalized lower MN involvement. Although none of the regions meet the EMG 
criteria for lower MN involvement the study was suggestive for generalized lower MN 
involvement due to signs of chronic Denervation in all four body regions. Ultrasono-
graphy showed increased echo intensity of the upper limb muscles only (z-scores 
between 1.5 and 2.5) and fasciculations in all measured muscles of the upper and 
lower limbs. 
III. A 79-year-old female with mononeuropathia multiplex. The ultrasound examination 
revealed fasciculations in all muscles of the upper and lower limbs, except for the 
right tibial anterior muscle. Echo intensity was increased in the forearm flexors (2.2 
right, 1.6 left), quadriceps (2.4 right, 2.8 left) and tibialis anterior (3.5 right, 3.1 left). 
IV. A 72-year-old patient with severe sensomotor axonal polyneuropathy and beta 
sympathicomimetics induced fasciculations. The ultrasound examination revealed 
fasciculations in all muscles of the upper and the lower limbs, except the left biceps, 
and one rectus abdominis muscle. The echo intensity was increased in the forearm 
flexors, biceps and left quadriceps (z-scores between 1.5 and 2.7). 
V. A 36-year-old male with a benign cramp fasciculations syndrome. This patient was 
the only one of the 4 patients with a benign cramp fasciculation syndrome, with 
a false positive ultrasound study. The ultrasound examination showed a marginal 
increased echo intensity of the sternocleidomastoid on both sides, right biceps, and 
right forearm flexors (z-scores between 1.5 and 1.7). Fasciculations were discovered 
in all measured muscles of the lower limb and the left rectus abdominis. 
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ABSTRACT
We performed a longitudinal study to assess structural muscle changes in amyotrophic 
lateral sclerosis (ALS) using ultrasonography. During a follow-up of 6 months, ultrasono-
graphy parameters (muscle thickness, echo intensity and fasciculations) were obtained 
from 6 muscle groups in 31 ALS patients, together with strength and scores on the 
revised ALS functional rating scale (ALSFRS-r). At baseline, we found an increased echo 
intensity and decreased thickness, and these parameters correlated with lower strength. 
Moreover, ultrasound abnormalities were also detected in muscles with preserved 
strength. Longitudinal changes in echo intensity, muscle thickness and fasciculations 
showed large variations between patients. Rates of change in ultrasound parameters did 
not correlate with changes in ALSFRS-r or strength. In conclusion, in patients with ALS 
ultrasound abnormalities can be found in muscles with preserved strength. The pattern 
of ultrasonographic muscle changes in ALS is highly variable and shows no evident 
correlation with functional measures. 
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INTRODUCTION
Amyotrophic lateral sclerosis (ALS) characteristically presents as a focal disease, with a 
combination of upper and lower motor neuron symptoms restricted to one body region.1 
Symptoms then spread to other regions, ultimately leading to death with a median 
survival time of 28 months after symptom onset.2 The phenotype of ALS is highly hetero-
geneous due to marked differences in region of onset, the relative mix of upper and lower 
motor neuron involvement and the rate of disease progression.3
Muscle ultrasonography is an easily accessible, inexpensive and painless method 
to detect structural muscle changes caused by neuromuscular diseases.4 Affected 
muscles show a diminished muscle thickness and appear whiter (i.e. have an increased 
echo intensity).4 Previously, we have shown that already in the diagnostic phase of ALS, 
ultrasonography reveals marked abnormalities, such as diminished thickness, increased 
echo intensity and fasciculations.5 The objective of the present longitudinal study 
was to visualize ALS related muscle changes during a follow up period of 6 months. 
Furthermore, we compared ultrasonography to manual muscle testing and the re vised 
ALS functional rating scale (ALSFRS-r) to assess the validity of ultrasonography to 
monitor disease progression in ALS. 
METHODS 
Subjects
We included 31 patients, in the following categories: possible ALS (n= 7), probable ALS 
laboratory-supported (n=13), probable ALS (n= 9) or definite ALS (n = 2) according to 
the revised El Escorial Criteria.6 We planned to evaluate each patient five times with an 
interval of six weeks. The local ethical committee approved the study and all patients 
gave written informed consent.
ALSFRS-r and muscle strength 
The ALSFRS-r was used to quantify activities of daily living.7 It consists of 12 items with 
scores ranging from 0 to 4, with a maximum achievable score of 48 (0 = total disability, 
48 = normal).
Muscle strength of 10 different muscle groups was manually tested, and scored 
with the modified scale of the Medical Research Council (9-grade; MRC 5 = 5.00; 
MRC 5- = 4.67; MRC 4+ = 4.33; MRC 4 = 4.00; MRC 4- = 3.67; MRC 3 = 3.00; MRC 
2 = 2.00; MRC 1 = 1.00; MRC 0 = 0.00).8 The muscle tested were neck flexors, neck 
extensors, and neck rotators, elbow flexors, wrist extensors and flexors, finger extensors 
and flexors, hip flexors, knee extensors and foot dorsiflexors on both sides. The total sum 
score was calculated, with a maximum achievable score of 100. 
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Ultrasonography 
Using a standard protocol,5, 9 ultrasound scans were made of the following muscles or 
muscle groups on both sides: sternocleidomastoid (representing the bulbar region), 
biceps brachii including the underlying brachialis muscle, forearm flexors, forearm 
extensors (cervical region), quadriceps femoris and tibialis anterior (lumbosacral region). 
All scans were made in the transverse plane with a standard transducer location 
corresponding to the muscle belly (Supplementary Table 1). For each muscle, three 
consecutive measurements were taken in order to minimize variation in echo intensity. 
Due to malfunction of the ultrasound device, we had to use a second apparatus. 
Measure ments were performed using either a Philips IU22 with a 5-17 MHz linear broad-
band transducer or a HP Sonos 2000 phased-array real-time scanner with a 7.5-MHz 
trans ducer. Consecutive measurements in a single patient were done using the same 
ultrasound device. The system settings and conversion procedure to combine results of 
the two devices have been described elsewhere.10
 
Measurement of muscle thickness and echo intensity
Muscle thickness was measured with electronic calipers placed at standardized locations 
(Supplementary Table 1). The ultrasound images were stored for further evaluation 
offline. Using customized image analysis software that was developed at our department 
(Qumia), a region of interest was selected in each muscle image. This region of interest 
included as much of the muscle as possible without any bone or surrounding tissue. 
The mean echo intensity of this region was calculated and averaged over the three 
measurements per muscle. In the quadriceps femoris, the rectus femoris muscle was 
used for analysis, because the outlines of the vastus intermedius muscle can be difficult 
to define in neuromuscular disorders.
 
Muscle fasciculations
Each muscle was screened for fasciculations during 10 seconds, according to previously 
published protocols.5, 11 Muscle movements were classified as fasciculations if they 
appeared as involuntary twitching of small parts of the muscle for at least two times. 
They could easily be distinguished from other movements like arterial pulsations 
(uni focal, rhythmic) or voluntary movements (involving the entire muscle).12-14
Analysis
Data were analyzed using SPSS for Windows 16.0. (SPSS Inc., Chicago, IL, USA). 
Muscle thickness and echo intensity were corrected for age, gender and handedness 
and transformed into z-scores,9 reflecting the number of standard deviations a measure 
differs from normal.
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Baseline assessment
One-sample t-tests were used to analyze baseline echo intensity and muscle thickness 
values. Spearman’s correlation coefficients were calculated to determine if baseline 
muscle thickness and echo intensity were related to strength of individual muscles or 
muscle groups. All measured muscles at baseline were divided in muscles with pre-
served strength (MRC 5) and paretic muscles. Scatter plots were used to explore these 
groups for differences in echo intensity and muscle thickness. A Mann-Whitney U-test 
was used to compare muscle with fasciculations to those without for difference in echo 
intensity, thickness or strength. 
Rate of change
For each time point, summed total body scores for echo intensity, thickness and strength 
were determined. For patients who finished at least three measurements, the rate of 
change of echo intensity, thickness, the number of muscles with fasciculations, strength, 
and ALSFRS-r were calculated. The scales of these parameters differ in ranges and 
directions; therefore each measurement was expressed as percentage of baseline. Linear 
regression equations were used to determine the rate of change per month. Similarly, the 
rates of change of echo intensity, thickness and strength were calculated for the different 
body regions (bulbar, cervical, lumbar) and each muscle separately. Pearson correlation 
coefficients were calculated to test for correlations between the rates of change of the 
different parameters. 
RESULTS
Subjects
Thirty-one patients entered the study. A total of 13 patients completed all five measure-
ments (possible ALS [n = 2], probable ALS laboratory-supported [n = 6], probable 
ALS [n = 5]). An additional nine patients had three or four measurements (possible 
ALS [n = 3], probable ALS laboratory-supported [n = 5], definite ALS [n=1]). These 
22 patients with at least three measurements were included for further analysis of the 
longitudinal data. In table 1, the clinical characteristics of the patients who finished at 
least three measurements were compared to the patients with early drop out. Decreased 
mobility was the most mentioned reason (seven patients) for early drop out. This is 
reflected in lower baseline strength and ALSFRS-r scores for this group. The remaining 
two patients dropped out because of psychological consequences of the confrontation 
with functional decline and transfer to another hospital, respectively. 
112 Monitoring disease progression Monitoring disease progression 
TABLE 1 Baseline characteristics
< 3 measurements
n = 9
≥ 3 measurements
n = 22
P-value
Males, n (%) 3 (33.3%) 16 (72.7 %) 0.044
Weight, kg 75,2 ± 8.6 (64-86) 77.9 ± 11.6 (53-93) 0.537
Age, yr 57,6 ± 13,8 (37-77) 61.5 ± 11.8 (40-79) 0.434
Disease onset – diagnosis, 
months 
11,0 ± 6,9 (5-26) 15.0 ± 9.1 (3-39) 0.596
Diagnosis – ultrasonography, 
months 
8,3 ± 6,6 (1-20) 7.0 ± 5.7 (2-18) 0.248
Disease onset, n (%)
Bulbar
thoracic
upper limbs
lower limbs
upper and lower limbs
2 (22.2%)
0
4 (44.4%)
3 (33.3%)
0
0
1 (4.5%)
8 (36.4%)
11 (50%)
2 (9.1%)
0.236
Strength (max 100) 75.7 ± 11.2 (59-89) 88.0 ± 10.1 (57-99) 0.008
ALSFRS-r (max 48) 31.1 ± 6.5 (22-42) 37.1 ± 6.3 (18-46) 0.025
Data are presented as means ± SD (range)
Baseline assessments
At baseline, thickness was decreased in all muscles except for the sternocleidomastoid 
and tibialis anterior muscle. Echo intensity was increased in all muscles except for the 
quadriceps (Supplementary Table 2). Echo intensity was affected to a greater degree than 
thickness. Fasciculations were found in an average of 8.1 out of 12 measured muscle 
groups (SD 2.69, range 2-12,). There were no differences in echo intensity, strength or 
thickness between muscles with and muscles without fasciculations. Baseline results 
were not influenced by type of ultrasound machine. 
At baseline, the weakest muscles showed the highest echo intensity and the smallest 
thickness (Figure 1). Strength was correlated with echo intensity and thickness of the 
biceps brachii muscle, forearm flexors, forearm extensors and the tibialis anterior muscle 
(Table 2). The sternocleidomastoideus showed a correlation between echo intensity 
and strength, but not between thickness and strength. Muscle thickness, but not echo 
intensity of the quadriceps was related to strength (Table 2). 
As expected, ultrasonography abnormalities (echo intensity >2 or muscle thickness <-2) 
were prevalent in paretic muscles (71.1% of muscles with MRC < 5). Strikingly however, 
30.4% of muscles with preserved strength showed ultrasonography abnormalities as well 
(Figure 2). This was even more apparent for fasciculations, present in 76.0% of paretic 
muscles, and in 62.6% of muscles with preserved strength.
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FIGURE 1
Baseline standardized muscle thickness and echo intensity as a function of strength, for the individual 
muscles and muscle groups. In this figure MRC grade 5-, 4+, 4 and 4- were combined into one group: 
MRC grade 4.   
FIGURE 2
Muscle thickness as a function of echo intensity for either muscles with preserved strength or 
paretic muscles.  
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TABLE 2 Correlation between strength, ALSFRS-r and ultrasonography parameters
Muscle thickness Echo intensity
Correlation P-value Correlation P-value
Baseline: strength for each muscle  
Sternocleidomastoid 0.247 0.057 -0.315 0.014*
Biceps brachii 0.526 <0.001* -0.318 0.012*
Forearm flexors 0.512 <0.001* -0.474 <0.001*
Forearm extensors 0.693 <0.001* -0.480 <0.001*
Quadriceps femoris 0.382 0.002* -0.176 0.175
Tibialis anterior 0.676 <0.001* -0.660 <0.001*
Rate of change: summed total body scores
Strength 0.187 0.405 -0.297 0.180
ALSFRS-r 0.339 0.123 -0.045 0.842
Rate of change: strength summed regional scores
Bulbar 0.000 0.999 -0.154 0.494
Cervical 0.040 0.860 -0.076 0.738
Lumbosacral 0.205 0.360 -0.487   0.021*
Rate of change: strength for each muscle
Sternocleidomastoid -0.056 0.717 -0.155 0.315
Biceps brachii -0.082 0.599 -0.049 0.754
Forearm flexors -0.054 0.728 0.054 0.727
Forearm extensors 0.141 0.363 -0.066 0.671
Quadriceps femoris 0.250 0.102 -0.228 0.137
Tibialis anterior 0.382  0.010* -0.017 0.911
Significant results are marked by *
Rate of change
During follow up, we expected thickness, ALSFRS-r and strength to decline and echo 
intensity to increase. However the observed ultrasound patterns showed more diversity, 
as illustrated in the biceps brachii of three patients (figure 3). 
Longitudinal data for ultrasound parameters, strength and ALSFRS-r scores for all 
patients are shown in figure 4. Clearly, a variety of different patterns are seen, with only 
eight patients in whom all parameters followed the anticipated direction. The changes 
in the number of muscles with fasciculations also showed large variety: in 9 patients the 
number of muscles with fasciculations increased during disease duration, 12 patients 
showed a decrease and 1 patient showed no change.
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FIGURE 3
Examples of ultrasonograms of the biceps brachii in 3 patients at baseline, 3 months and 6 months. 
Patient A, a 43-year-old male with short disease duration and slow disease progression. Here, we 
found the expected pattern with decline of muscle thickness (z-scores at baseline, 3 and 6 months: 
0.8; 0.0; -0.1) and increase of echo intensity (-0.1; 1.1; 1.4) during time. Patient B, a 44-year-old female 
with long disease duration and slow disease progression, revealed strongly increased echo intensity 
and decreased muscle thickness at baseline. During follow up both echo intensity (5.1; 6.5; 4.7) and 
thickness (-2.8; -3.8; -2.5) showed no evident changes. Patient C was a 64-years-old male with short 
disease duration and very fast disease progression. Over 6 months, both echo intensity (2.1; 1.2; 2.7) 
and muscle thickness (-1.0; 0.2; 0.8) mildly increased.  
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FIGURE 4
Individual changes in time, for muscle thickness, echo intensity, fasciculations, strength and ALSFRS-r 
(expressed as percentage of baseline). Muscle thickness, echo intensity, and strength are summed 
scores over all muscle groups.    
The mean rates of change (% per month compared to baseline) were as follows: echo 
intensity 1.29 ± 3.54; muscle thickness -0.76 ± 1.26; number of muscles with fasci-
culations 0.59 ± 7.98; strength -1.42 ± 1.50 and ALSFRS-r -1.34 ± 1.98. The rate of 
change of the ALSFRS-r correlated with strength (r= 0.578, p= 0.005). However, the 
rate of change of the ultrasound parameters did not correlate with each other or with the 
ALSFRS-r or strength (table 2). At the regional or muscle level, correlations were absent 
as well. Longitudinal changes in echo intensity showed a larger variation using the HP 
Sonos 2000. However, the lack of correlation between strength / ALSFRS-r and echo 
intensity rate of change was found using either ultrasound device. 
DISCUSSION
We showed that ultrasonography reveals decreased muscle thickness, increased echo 
intensity and fasciculations in ALS. Moreover, thickness and echo intensity were correlated 
with strength. Ultrasonography changes during a 6 month follow-up showed a large 
diversity and did not correlate with changes in ALSFRS-r or strength. 
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At baseline, even muscles with preserved strength already showed ultrasonographic 
abnormalities like fasciculations and increases in echo intensity. Higher echo intensity is 
caused by increased amounts of intramuscular fibrous and fatty tissue,15 secondary to 
denervation.16 In addition, fasciculations in ALS are considered to be a sign of denervation 
as well.17 As denervation already takes place before muscles become paretic,16, 18 this 
may explain the baseline ultrasound findings. These results suggest that ultrasonography 
might be used to increase diagnostic certainty, in the same way as EMG is currently used 
to detect subclinically affected muscles.6
The longitudinal changes in ultrasound parameters showed more variety than expected. 
Moreover, ultrasound changes did not correlate with rates of change of ALSFRS-r and 
strength. Ultrasonography therefore does not seem to be a suitable method to monitor 
disease progression in clinical trials. Ultrasonography may be useful in other areas 
however: not only can it detect structural muscle changes in an early phase of the disease, 
we have also shown that baseline echo intensity values can be used to predict 
survival.19
One explanation for the differences between changes in strength, ALSFRS-r and 
ultra sonography might be that ultrasonography mainly detects lower motor neuron 
involvement.20 Progressive upper motor neuron involvement will lead to decreased 
strength and ALSFRS-r scores but will not affect ultrasonography parameters. Another 
explanation may be the fact that strength and ultrasound parameters were not obtained 
in completely the same muscles. However, results did not change when we ran the 
analysis using a compound MRC score including only those muscles also studied with 
ultrasound (data not shown). 
Additional analysis (data not showns) revealed that the use of two different ultrasound 
devices and transducers had no relevant implications for the results. Baseline results were 
comparable for both ultrasound devices. Longitudinal changes in echo intensity showed 
larger variation with the HP Sonos 2000 with a linear broadband transducer. However 
this did not essentially influence our results; the rate of change of echo intensity did not 
correlate with strength or ALSFRS-r using either the Philips IU22 or the HP Sonos 2000.
Although atrophy is a characteristic feature of ALS, muscles became thicker in some 
patients during the 6 months follow-up. This could be explained by training effects, such 
as the start of physical therapy, or increased use of muscle to compensate for paretic 
ones. Increased muscle strength as a result of training is described before in ALS.21 
Reinnervation has also been suggested as a source for temporarily gain of muscle 
strength.18 
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In some patients, echo intensity decreased in time. This is remarkable, since intra-
muscular fibrous and fatty tissue due to denervation is thought to be irreversible, 
especially in a progressive disease like ALS. However it is known that increases of the 
relative amount of echo dense material like endo- and perimysium, due to muscle fiber 
atrophy, also result in higher echo intensity.22 The decreased echo intensity might therefore 
be the result of increased muscle fiber size, for example due to training. Attenuation of the 
ultrasound beam due to high fibrous/fat content in severely affected muscles might be 
another reason for decreased echo intensity during disease course. However, muscles 
with higher echo intensity at baseline did not show different patterns of intensity changes 
over time (data not shown). 
In our study population, there was a relatively slow disease progression, with a relative 
decrease in ALSFRS-r scores of 1.3% per month to baseline. In absolute values, this 
represents a decline of 0.7 points per month, lower that the previously published average 
decline of 0.9 points per month.23 It is likely that patients with faster disease progression 
were the ones that lacked enough evaluation time points to be included in the analysis, 
biasing our findings towards a slower disease progression.
Conclusion
The pattern of ultrasonographic muscle changes in ALS is highly variable and shows no 
evident correlation with functional measures like strength. However, ultrasonography can 
be used to detect abnormalities in clinically normal muscles. It would be interesting to 
compare ultrasound findings with electrophysiological studies, including needle EMG, in 
clinically normal muscles. The exact role of ultrasound on the diagnostic process of ALS 
-including its cost-effectiveness- should be determined by future studies. 
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SUPPLEMENTARY TABLE 1 Examined muscle (groups) with corresponding transducer location  
        and caliper position for thickness measurement
Transducer location Caliper position
SCM ½ distance mastoid bone – cranial 
sternal margin
dorsal fascia SCM – ventral fascia 
SCM
Biceps brachii ⅔ distance acromion – antecubital 
crease
upper margin humerus – ventral fascia 
biceps
Forearm flexors ⅖ distance antecubital crease – distal 
end radius
interosseus membrane – ventral fascia 
most superficial flexors
Forearm extensors ½ distance antecubital crease – distal 
end ulna
interosseus membrane – dorsal fascia 
most superficial flexors
Quadriceps femoris ½ distance anterior superior iliac  
spine – superior aspect patella
upper margin femoral bone – ventral 
fascia rectus femoris
Tibialis anterior ¼ distance inferior aspect patella – 
lateral malleolus
interosseous membrane – ventral 
fascia tibialis anterior  
SCM; sternocleidomastoid
 
SUPPLEMENTARY TABLE 2 Mean standardized echo intensity and muscle thickness (z-score)  
        of patients with ALS at baseline
Muscle thickness P-value Echo intensity P-value
SCM L -0.45 ± 1.62 (-4.2 – 2.7) 0.132 1.37 ± 1.68 (-1.5 – 8.2) <0.001
R -0.60 ± 1.57 (-5.0 – 3.3) 0.043 1.35 ± 1.48 (-1.2 – 6.6) <0.001
Biceps
brachii
L -0.90 ± 1.73 (-4.3 – 1.5) 0.006 1.76 ± 1.78 (-1.5 – 5.8) <0.001
R -1.33 ± 2.17 (-7.2 – 1.9) 0.002 1.56 ± 1.59 (-0.8 – 5.9) <0.001
Forearm
flexors
L -1.37 ± 1.78 (-5.5 – 1.5) <0.001 3.15 ± 1.80 (0.7 – 7.6) <0.001
R -1.00 ± 1.35 (-4.6 – 1.5) <0.001 2.70 ± 1.75 (-0.7 – 7.6) <0.001
Forearm
extensors
L -1.74 ± 1.84 (-6.8 – 2.0) <0.001 2.70 ± 1.82 (-0.3 – 7.4) <0.001
R -1.36 ± 1.64 (-5.5 – 1.7) <0.001 2.51 ± 1.66 (-0.5 – 7.1) <0.001
Quadriceps
femoris
L -1.11 ± 1.92 (-4.8 – 1.7) 0.002 0.33 ± 1.44 (-2.6 – 2.6) 0.212
R -1.13 ± 1.90 (-6.0 – 1.8) 0.003 0.06 ± 1.38 (-2.5 – 3.4) 0.820
Tibialis
anterior
L -0.27 ± 1.19 (-3.2 – 1.8) 0.210 1.60 ± 1.64 (-0.6 – 6.8) <0.001
R -0.35 ± 1.26 (-2.7 – 2.2) 0.127 1.54 ± 1.34 (-0.6 – 5.6) <0.001
Data are presented in means ± SD (range). Abbreviations used: L: left, R: right, SCM: sternocleidomastoid
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 ABSTRACT 
We assessed the prognostic value of muscle ultrasonography in 31 patients with amyo-
trophic lateral sclerosis (ALS) and compared it with accepted prognostic variables like 
functional capacity (measured with the ALSFRS-R rating scale) and muscle strength. 
Each patient was examined once. The following ultrasonography parameters were 
determined: muscle thickness, echo intensity and the presence of fasciculations. 
Correlations between baseline measurements, preslope values and survival were 
calculated. Echo intensity, disease duration, muscle strength preslope and ALSFRS-R 
preslope correlated with survival. Using a stepwise multivariate analysis, the combination 
of echo intensity preslope and ALSFRS-R preslope was shown to have the best predictive 
value for survival.
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INTRODUCTION
Survival is an important and frequently used outcome measure for clinical trials in amyo-
trophic lateral sclerosis (ALS).1, 2 The median survival time from diagnosis is estimated 
to be around 15 months.3 However, more than 25% of patients live longer than 4 years.3 
Due to this large interindividual variation, the use of survival as a primary outcome 
measure leads to studies with large sample sizes and long duration.3-6 One possible 
solution to compensate for population heterogeneity is the use of prognostic variables for 
stratification. Examples of such variables are age, time from symptom onset to 
diagnosis, and functional capacity as measured with the revised ALS Functional Rating 
Scale (ALSFRS-R).3, 5-7  
Ultrasonography, a painless and relatively simple technique, can be used to visualize 
structural muscle changes caused by a neuromuscular disorder.8 Affected muscles show 
a diminished muscle thickness and appear whiter (i.e. have an increased echo intensity).8 
Aging also results in diminished muscle thickness and increased echo intensity.8 By 
quantitative analysis, with use of age and gender based normal values, it is possible 
to discriminate between neuromuscular and non-neuromuscular diseases with high 
sensitivity and specificity.8 Furthermore, due to its capability to register movements, 
ultrasonography is a highly sensitive tool to reveal fasciculations. Recently we showed 
that even in an early stage of ALS, atrophy, increased echo intensity and fasciculations 
could be detected.9 
 
Here, we studied whether muscle ultrasonography can be used as an additional 
prognostic tool to predict survival in patients with ALS.
METHODS 
Subjects
We included 31 patients with probable, possible or definite ALS according to the El 
Escorial Criteria.10 Patients were examined once. Recordings included measurements of 
muscle strength, ALSFRS-R and muscle ultrasonography. Outcome was retrieved from 
the medical records. The survival time, defined as the time from symptom onset, was 
estimated using medical records. The local ethical committee approved the study and all 
patients gave written informed consent.
Ultrasonography 
Using a standard protocol,9 transverse ultrasound scans were made of the following 
muscles or muscle groups on both sides: sternocleidomastoid, biceps brachii including 
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the underlying brachialis muscle, forearm flexors, quadriceps femoris and tibialis anterior. 
Measurements were performed using either a Philips IU22 with a 5-17 MHz linear broad-
band transducer or a HP Sonos 2000 phased-array real-time scanner with a 7.5-MHz 
transducer. The system settings and conversion procedure to combine results from 
the two scanners have been described elsewhere.11 Thickness and echo intensity of 
each muscle were determined using standardized procedures.9 Furthermore, each 
muscle(group) was screened for fasciculations during 10 seconds.9
Muscle strength and ALSFRS-R
Muscle strength of 10 different muscle groups of the neck, upper and lower limbs 
was manually tested on both sides, and scored with the modified scale of the Medical 
Research Council.12 The total sum score was calculated, with a maximum score of 100. 
The ALSFRS-R was used to quantify activities of daily living.13 The ALSFRS-R consists 
of 12 items with scores ranging from 0 to 4, with a maximum achievable score of 48 
(0 = total disability, 48 = normal).
Analysis
Data were analyzed using SPSS V16.0. Data are shown as mean ± SD (range). 
Muscle thickness and echo intensity were corrected for age, gender and handedness 
and transformed into z-scores, which were then summed to yield a composite z-score 
(with a normal value of 0). 
The prognostic value of each variable was expressed in terms of a hazard ratio using 
univariate analysis. For the factors reaching significance in this test, adjusted hazard 
ratios were estimated by multivariate analyses (forward conditional method) using a 
Cox proportional hazards regression model. Tested variables included age, disease 
duration, number of muscles with fasciculations, and baseline values of echo intensity, 
muscle thickness, ALSFRS-R and strength. In addition, preslope values of echo intensity, 
muscle thickness, ALSFRS-R and strength were calculated and tested as prognostic 
variable. Preslope values – the estimated rate of change of outcome measures prior to first 
examination- have shown to be good predictors of survival in various studies.5, 6, 14 
Preslope values were computed as follows: (measured value – normal value) / disease 
duration. The relation between the different variables was assessed using Spearman’s 
correlation coefficients.
RESULTS
A total of 31 patients were included (19 males), with an age of 60.4 years ± 12.4 (37-80) 
and weight of 77.1 kg ± 10.7 (53-93). Six patients were classified as possible, 22 as 
probable, 2 as definite and 1 patient as familial ALS. They all used riluzole. The diagnosis 
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was established 13.8 months ± 8.6 (3-39) after symptom onset. Ultrasonography 
examination was performed 21.2 months ± 10.4 (5.2-51.4) after presenting symptoms. 
At that time the mean ALSFRS-R score was 35.4 ± 6.8 (18-46) and the mean muscle 
strength 84.7 ± 11.6 (57-99). At the time of analysis -approximately 6 months after 
inclusion of the last patient- 16 out of 31 patients (51.6%) were deceased.
Patients showed a reduced muscle thickness, total z-score: -11.6 ± 13.1 (-38.8 – 12.2) 
and increased echo intensity: total z-score 22.0 ± 13.9 (5-68.5). The average number of 
muscles showing fasciculations was 6.6 (range 1-10).  
Table 1 displays the results of the univariate and multivariate analysis to predict survival. 
As reported before,3, 5, 6 shorter disease duration, and lower ALSFRS-R preslope were 
individually associated with a shorter survival. Furthermore, lower muscle strength preslope 
was correlated with a worse prognosis. Of the ultrasound measures, higher echo intensity 
preslope values significantly predicted shorter survival as well. 
TABLE 1 Cox proportional hazard analysis to predict survival
Univariate Multivariate
Hazard ratio (95% CI) p Hazard ratio (95% CI) p
Age 1.02 (0.97 - 1.06) 0.471
Gender 1.27 (0.47 -3.38) 0.637
Weight 0.98 (0.93 - 1.02) 0.318
Disease onset - diagnosis 0.93 (0.86 - 1.00) 0.052
Disease onset - ultrasound 0.94 (0.89 - 0.99) 0.020
Number of muscles with 
fasciculations
1.09 (0.89 – 1.33) 0.388
Total muscle thickness 1.00 (0.96 - 1.06) 0.830
Total EI 1.01 (0.98 - 1.05) 0.574
Total strength 0.98 (0.94 - 1.01) 0.171
Total ALSFRS-R 0.96 (0.90 - 1.02) 0.162
EI preslope 4.72 (2.02 – 11.03)  0.001 4.88 (1.06 – 22.44) 0.042
Muscle thickness preslope 0.89 (0.38 – 2.07) 0.774
Strength preslope 0.08 (0.03 – 0.25) < 0.001
ALSFRS-R preslope 0.021 (0.003 – 0.15) < 0.001 0.019 (0.002 – 0.23) 0.002
Stepwise multivariate analysis revealed a predictive model that only included the echo 
intensity preslope and ALSFRS-R preslope as prognostic variables. Although being an 
individual predictor of survival, muscle strength preslope was not of additional value to 
the multivariate predictive model. This may be due to the strong correlation between 
muscle strength and ALSFRS-R preslope (correlation coefficient 0.74, p <0.001). 
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The correlation between echo intensity and ALSFRS-R preslope was relatively weak 
(correlation coefficient -0.41, p = 0.05), indicating that these are independent predictors. 
The correlation coefficients of the other preslope parameters were as follows: ALSFRS-R 
- muscle thickness: 0.18 (p = 0.344), muscle thickness - echo intensity: -0.45 (p = 0.011) 
and echo intensity - strength preslope: -0.51 (p = 0.004). 
FIGURE
Kaplan-Meier plot describing overall cumulative survival (A) and cumulative survival after stratification 
by ALSFRS-R preslope (B), echo intensity preslope (C) or the combination of echo intensity and ALS-
FRS-R preslope (D). The small vertical lines represent censored cases. In plot B and C median values 
of ALSFRS-R and echo intensity preslope were used as cut-off values respectively. In plot D, 33th and 
67th percentiles were used as cut off.  
Abbreviations: EI-p – echo intensity preslope, ALSFRS-p - ALSFRS-R preslope. 
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The prognostic value of both echo intensity and ALSFRS-R preslope is further illustrated 
by Kaplan-Meier plots, showing clear differences in survival when stratified using echo 
intensity or ALSFRS-R preslope or the combination of both (Figure). 
DISCUSSION
Our study shows that an increased muscle echo intensity preslope predicts survival in 
patients with ALS. Moreover, increased echo intensity had additional prognostic value when 
combined with the ALSFRS-R preslope, an already accepted predictor for survival.1, 5, 6 
The independent value of both measures is supported by their rather low correlation, 
suggesting they represent different aspects of the disease process in ALS. The number 
of fasciculations did not predict survival. 
Although muscle strength preslope was strongly predictive for survival in the 
univariate analysis is, it did not emerge as an additional predictive parameter in the 
stepwise multivariate analysis. Most likely, this was due to the strong correlation between 
muscle strength and the ALSFRS-R preslope, so adding muscle strength to the model 
did not increase its predictive value.
Preslope values were better predictors of survival than baseline values or disease 
duration. Preslope values combine these two aspects, probably making these a better 
indicator of the rate of “preclinical” disease progression. A practical advantage of 
preslope values is the fact that they are based on just one evaluation point that can 
be routinely acquired during the diagnostic process. In addition, preslope values are 
convenient in clinical trials, since these do not require a lead-in period.4 However, it would 
be useful to directly compare preslope ultrasonography measures with a longitudinal 
repeated measures design as a final ‘validation’.
Echo intensity preslope was a good predictor of survival, in contrast to muscle thickness. 
This may be due to the fact that echo intensity is the result of intramuscular fatty or fibrous 
tissue, an irreversible consequence of denervation.15, 16 In contrast, muscle atrophy is 
not only caused by denervation but is also the result of other factors like disuse. Training 
and reinnervation can temporarily prevent muscle atrophy, but will not have considerable 
effects on the amount of intramuscular fatty or fibrous tissue.
The significant results in this relatively small study further show the strength of echo 
intensity preslope as a predictor for survival. However, precise cut-off values need to be 
established in a large follow-up trial. 
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SUMMARY
MUSCLE ULTRASOUND IN HEALTHY ADULTS
In this part of the thesis we explored the effect of gender and age on muscles, obtained 
normal values for muscle thickness and echo intensity and assessed the prevalence of 
fasciculations in healthy individuals.
Muscle thickness
In chapter 2.1 and chapter 2.2 we describe normative data for muscle thickness and 
illustrate the impact of age on muscle thickness. In 194 healthy individuals (103 males), 
aged 2 months to 90 years, transverse ultrasound scans were made of the biceps 
and quadriceps femoris muscles (chapter 2.1). In 95 of these subjects, aged 17-90, 
the sterno cleidomastoideus, forearm flexors and tibialis anterior were also measured 
(chapter 2.2). Muscle thickness was strongly influenced by age. Up to age 20, muscle 
thickness increased steeply. The peak muscle thickness was reached between 30-40 
years. After that age, muscle thickness declined. This decrease was muscle and gender 
specific and ranged from 0-50%. The greatest decline occurred in the thickest muscles, 
the largest declines were found in the quadriceps in men. The upper limb muscles 
also demonstrated left-right differences. These findings were discussed in the light of 
sarcopenia, the age related decline in muscle mass.
Muscle thickness depends on age, gender and - in the upper limbs - on side of 
the body. 
Echo intensity
In chapter 2.2 we present normative data for echo intensity for five different muscles. 
Bilateral scans of the sternocleidomastoid, biceps brachii, forearm flexors, quadriceps 
femoris and tibialis anterior were made in 95 volunteers aged 17-90 years. Echo intensity 
showed gender differences and a muscle specific non-linear correlation with age. The 
upper limb musculature and the tibialis anterior also demonstrate left-right differences. 
The average echo intensity ranged from 25 – 34 in men and 30 – 40 in women, with the 
lowest echo intensity in the quadriceps femoris and the highest in the tibialis anterior. 
Echo intensity increased with age, especially from the age of 60. This age related 
increase in echo intensity was gender and muscle specific. At the age of 90, the echo 
intensity was approximately 30 - 45 in men and 30 - 50 in women.
Echo intensity is age, gender and muscle specific. The upper limb musculature and
the tibialis anterior also show left-right differences.
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Fasciculations
In chapter 2.3 we determined the prevalence and distribution of fasciculations in 
58 healthy adults and assessed the effect of age, caffeine and exercise. In an additional 
10 healthy adults we tested the effect of strenuous exercise on fasciculations. With 
10 seconds screening per muscle, 43% of all healthy subject showed fasciculations, 
mostly in the abductor hallucis longus. Fasciculations were only sporadically encountered 
in muscles above the knee. Subjects with fasciculations were significantly older than 
those without. Caffeine and regular physical exercise did not influence the prevalence 
of fasciculations. However, strenuous physical exercise caused a temporary increase in 
fasciculations.
Fasciculations can be detected in healthy individuals, especially in the distal muscles of 
the lower limb. Age and strenuous exercise influence the occurrence of fasciculations, 
while caffeine and regular exercise do not.
MUSCLE ULTRASOUND IN ALS
In this part of the thesis we examined the clinical relevance of muscle ultrasonography in 
ALS: as a diagnostic tool, to predict survival and to monitor disease progression.
Ultrasound abnormalities in ALS
In chapter 3.1 we investigated whether quantitative muscle ultrasonography can detect 
structural muscle changes in early-stage ALS. Bilateral transverse scans were made of 
5 muscle groups (sternocleidomastoid, biceps brachii, forearm flexors, quadriceps 
femoris and tibialis anterior) in 48 patients with ALS. Twenty-five patients were also 
screened for fasciculations. Increased echo intensity was found in all muscles, 
decreased muscle thickness in the biceps brachii, forearm flexors and quadriceps 
femoris on both sides. Echo intensity was more abnormal than muscle thickness. Fasci-
culations were easy to detect in multiple muscles of all screened patients except one. The 
mean number of muscles with fasciculations was 6.5 out of the 10 measured muscles. 
In chapter 3.4 we showed that echo intensity and muscle thickness correlate with strength. 
Moreover, ultrasound abnormalities could be detected in muscles with preserved strength: 
approximately 30% of the muscles with preserved strength showed diminished muscle 
thickness or increased echo intensity and 63% fasciculations.  
Increased echo intensity, diminished muscle thickness and fasciculations can be 
detected in ALS, even in muscles with preserved strength. 
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Histopathological correlates
In chapter 3.2 we compared ultrasound results with post mortem muscle samples of 
an ALS patient. Transverse ultrasound scans were taken of nine muscles and compared 
with post-mortem total cross sectional muscle samples. Echo intensity was strongly 
correlated with the amount of intramuscular fibrous tissue (r = 0.86, p = 0.007), but not 
with intramuscular fat.
Echo intensity is strongly correlated with the amount of intramuscular fibrous tissue.
Diagnosis
In chapter 3.3 we tested whether muscle ultrasonography can differentiate between 
ALS and diseases with a similar presentation (so-called “mimics”). Ninety-five patients, 
suspected for adult onset motor neuron disease, were included in this prospective 
study. Ultrasound scans were made of 12 different muscle groups. Echo intensity was 
determined and each muscle was screened for fasciculations. The revised El Escorial 
criteria were used to establish the reference diagnosis. Ultrasonography was considered 
diagnostic for ALS when echo intensity was 1.5 SD above normal in at least 2 muscles 
and fasciculations were present in at least 4 muscles. Ultrasonography differentiated 
between ALS and mimics with 96% sensitivity and 84% specificity. In the 27 patients with 
ALS, ultrasonography detected 15 regions with lower motor neuron (MN) involvement 
that were negative using either clinical examination or needle electromyography (EMG).
Muscle ultrasound can differentiate between ALS and ALS-mimics with high sensitivity 
and specificity. It also is a sensitive tool to detect regional lower MN involvement.
Disease progression
In chapter 3.4 we focused on ultrasonographic structural muscle changes during 
disease course in ALS. In this longitudinal study with a 6 month follow-up, ultrasonography 
parameters (muscle thickness, echo intensity and fasciculations) were obtained from 
6 muscle groups in 31 ALS patients, together with strength and scores on the revised 
ALS functional rating scale (ALSFRS-r). Longitudinal changes in echo intensity, muscle 
thickness and fasciculations showed large variations between patients. Unexpectedly, 
some patients showed increases in muscle thickness or decreases in echo intensity 
during disease course. Rates of change in ultrasound parameters did not correlate with 
changes in ALSFRS-r or strength. 
Ultrasound is not suitable to monitor disease progression in ALS.
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Survival
In chapter 3.5 we studied the prognostic value of muscle ultrasonography in 31 patients 
with ALS and compared it with accepted prognostic variables like functional capacity 
(measured with the ALSFRS-R rating scale), disease duration, age and muscle strength. 
Each patient was examined once. Besides baseline values, also preslope values of echo 
intensity, muscle thickness and fasciculations were determined. Preslope values are 
the estimated rate of change of an outcome measures prior to first examination. Echo 
intensity preslope, disease duration, muscle strength preslope and ALSFRS-R preslope 
correlated with survival. Using a stepwise multivariate analysis, the combination of echo 
intensity preslope and ALSFRS-R preslope was shown to have the best predictive value 
for survival.
With a single ultrasound examination at baseline, survival can be predicted in ALS
DISCUSSION & PERSPECTIVES
ULTRASOUND IN HEALTHY ADULTS
Quantitative muscle ultrasound analysis
Neuromuscular ultrasonography has developed gradually over the past years, and now 
the point is reached that the technique moves from use in experimental study settings to 
daily clinical practice. The Association of Neuromuscular and Electrodiagnostic Medicine 
recently published a position statement regarding the qualifications for practitioners of 
neuromuscular ultrasound.1 One of the requirements is the understanding of imaging 
characteristics of normal and abnormal muscles. Since these characteristics change 
during life and are muscle and gender specific (chapter 2.2), quantification of diameter 
and gray scale seems to be the analyzing method of choice. Indeed, quantitative analysis 
is more objective, more sensitive to detect subtle changes in echo intensity and allows 
comprehensive statistical analysis.2 Of course, normal values are necessary to achieve 
this goal.  
One disadvantage of quantitative analysis that needs to be mentioned is the fact that 
normal values of echo intensity are ultrasound device dependent. Each ultrasound 
device requires its own set of normal values for echo intensity. However, the establish-
ment of new normal values for echo intensity can be simplified by using a conversion 
procedure.3    
Physiological factors influencing muscle ultrasound
With the interpretation of ultrasound results, physiological factors that may influence 
thickness or echo intensity have to be taken into account. With gender, age and handed-
ness we could explain approximately 70% of the variability in muscle thickness in men 
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and 50% in women, and 50% of the variability in echo intensity in men and 44% in women. 
Factors like resistance training4, 5, daily physical activity6 or hereditary predisposition7 are 
also known to effect muscle thickness. The only established influencing factor for echo 
intensity is obesity, leading to a higher echo intensity.8 Care has to be taken interpreting 
ultrasound results of individuals with an influencing factor at an extreme degree. In those 
cases intraindividual comparisons (left to right, upper to lower extremities, lower to distal 
musculature) might be helpful. 
Fasciculations in the healthy population
It is generally known that fasciculations can occur in healthy individuals. Still, the fact that 
they can be a manifestation of a progressive lower MN disease is often reason for referral 
to a neurologist. In chapter 2.3 we showed that 40% of healthy individuals reveal fascicu-
lations (with a 10 seconds screening per muscle protocol), almost always located in the 
distal muscles of the lower limbs. Strenuous exercise can lead to a temporary increase of 
fasciculations. These results suggest that fasciculations above the knee in an otherwise 
healthy subject, without preceding strenuous exercise, warrants further examination. 
Sarcopenia
Ultrasound can be used to detect sarcopenia, the age related decline in muscle mass. In 
chapter 2.1 we illustrated this striking impact of age on muscle thickness: the thickness of 
the quadriceps muscle of a 90-year-old man resembles that of a 5-year-old child. Hence, 
it is not surprising that sarcopenia is associated with increased tendency to fall and 
dependency.9 In additional, sarcopenia leads to increased nursing home admission and 
mortality.9, 10 Screening for sarcopenia seems usefull, since it can partially be reversed 
with resistance training, even in the very old.11  
MUSCLE ULTRASOUND IN ALS
Ultrasound alterations in ALS can be ascribed to lower MN dysfunction (Figure 1). Atrophy 
and fasciculations are generally regarded as symptoms of lower MN dysfunction.12 
Increased echo intensity in ALS is caused by increased intramuscular fibrous tissue 
(chapter 3.2), a phenomenon known to be related with denervation.13 An influence of 
upper MN involvement on ultrasound parameters cannot been ruled out. This is probably 
small however, as was already clear from studies in children.14  
The most apparent ultrasound abnormality in ALS is the presence of fasciculations 
(chapter 3.1 and 3.5). With a 10 second screening protocol per muscle, fasciculations 
can be detected in nearly all ALS patients (chapter 3.1). The least abnormal ultrasound 
parameter is muscle thickness (chapter 3.1). On a group level, the standardized muscle 
thickness, expressed in z-scores, ranges from -0.3 (sternocleidomastoid) to -1.4 (biceps), 
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while standardized echo intensity ranges from 1.0 (quadriceps) to 2.3 (forearm flexors). 
The reason for this relative preservation of muscle thickness, may be that reinnervation 
can temporarily compensate for loss of muscle mass.15 
FIGURE 1
Comparison of signs of lower motor neuron dysfunction with muscle histopathology, clinical examina-
tion and ultrasonography.    
Diagnosis
The diagnostic value of ultrasound in ALS and the sensitivity for the detection of 
regional lower MN involvement can for a large part be attributed to the high sensitivity of 
ultrasound in detecting fasciculations (chapter 3.5). Previous studies already showed that 
ultrasonography is more sensitive in detecting fasciculations than clinical examination or 
EMG.16, 17 Furthermore, ultrasonography is also reliable to screen for fasciculations. The 
interrater agreement for ultrasonography is higher than for clinical examination and equal 
to EMG .16   
The diagnostic value of fasciculations in the El Escorial criteria is limited.12 The main 
motivation for this was never formally stated, but is probably the fact that fasciculations 
are not specific for ALS. In the newer diagnostic criteria, the in 2008 developed Awaji 
criteria18, fasciculations potentials have an increased diagnostic importance (Box 1). 
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This did not result in a lower specificity.19, 20 Our results also suggest that the presences of 
(widespread) fasciculations might be used to increase sensitivity of diagnosis ALS 
without loss of specificity.
BOX 1 Awaji criteria   
Upper and lower MN degeneration
AND
Progression 
AND
Absence of evidence of other disease processes
lower + upper MN
 in 1 region
OR
upper MN in 2 regions
OR
lower above upper
MN signs
lower + upper MN
 in 2 regions
lower + upper MN 
in 3 regions
Possible ALS Probable ALS Definite ALS
The levels of diagnostic certainty according to the Awaji criteria are: possible, probable and definite 
ALS. The most important differences between the El Escorial criteria and the Awaji criteria are that 
neurophysiological evidence of lower motor neuron (MN) involvement is considered equivalent to 
clinical evidence, and the presence of fasciculation potentials is considered as important as fibrillation 
potentials or positive sharp waves. In all diagnostic levels lower MN involvement can be demonstrated 
by clinical examination or EMG. 
Disease progression 
Longitudinal changes in echo intensity, muscle thickness and fasciculations showed 
large variations between patients. In general, MN degeneration in ALS leads to a 
gradually increasing non-reversible atrophy. Unexpectedly, we found in some patients an 
increase in muscle thickness. This is probably the result of training or reinnervation, since 
these mechanisms have been described to increase strength in ALS patients.15, 21 
The rates of change in ultrasound parameters did not correlate with changes in ALSFRS-r 
or strength. The fact that muscle ultrasound was not able to detect disease progression 
in ALS was unexpected but is probably explained by the fact that ultrasonography mainly 
detects lower MN involvement. Progressive upper MN involvement will lead to decreased 
strength and ALSFRS-r scores but will not affect ultrasonography parameters. Also the 
heterogeneous study populations with large variations in the obtained parameters might 
have lead to lack in correlation. 
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Survival
With a one-time ultrasound examination at baseline, survival can be predicted in ALS 
patients. The best predictive multivariate model for survival consisted of the echo- 
intensity preslope and ALSFRS-r preslope. These preslope values represent the 
estimated rate of change of an outcome measures prior to first examination. Preslope 
values are good predictors; probably they give a better representation of progression 
because a time aspect is included. Before baseline ultrasonography can be used as 
prognostic variable, additional studies are required to confirm the predictive value of the 
echo-intensity preslope and to determine the most suitable cut-off value. 
Recommendations for future research
Decreased muscle thickness, increased echo intensity and the presence of fasciculations 
in itself are not specific for ALS.22 However, the combination and severity of the different 
ultrasound parameters and the pattern of affected muscles are indicative for a specific 
diagnosis22 and do result in a good diagnostic value for ALS. The potential of muscle 
ultrasound in ALS might be enhanced by a better knowledge of specific ultrasound 
findings in ALS-mimics. For example, ultrasound scans of IBM patients have a distinct 
appearance with severe atrophy and echo intensity values that are higher than those of 
patients with ALS.22 A combination of muscle and nerve ultrasonography might also lead 
to better diagnostic values. Using nerve ultrasonography, an increased nerve thickness 
can be detected in some ALS-mimics like multifocal motor neuropathy, hereditary motor 
and sensory neuropathy and chronic inflammatory demyelinating neuropathy.23, 24
Various studies have tried to differentiate between fasciculations in ALS and benign 
fasciculations based on EMG characteristics.25-27 Although the firing rate of fascicu-
lations in ALS compared to benign fasciculations is higher27 and fasciculation potential 
instability25 and F-waves occur more often26, none of those features are sufficiently 
discriminative.26, 27 Our study shows that with widespread prevalence of fasciculations, a 
good specificity can be reached (chapter 3.5). 
Recently it was described that fibrillations can be detected with ultrasonography.28 
Fibrillations appear as fine, non jerky, oscillating movements. Obviously the detection 
of fibrillations increases the capability of ultrasound in the diagnostic work-up of neuro-
muscular disorders. However, at this moment the sensitivity and specificity is limited and 
lower than that of EMG.28, 29 Among the factors that impede the detection of fibrillations 
is the presence of fasciculations.29 The displacement of muscle tissue by fasciculations 
“clouds” the fine oscillating movements of fibrillations. The detection of fibrillations with 
ultrasound may be improved by the development of newer ultrasound devices with 
higher resolution and frame rates. 
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Clinical implementation
In Figure 2, we propose how ultrasound can be implemented in the diagnostic work-up 
for ALS. A two step approach is described, which uses the same ultrasound examination. 
In the first step, the results of a “total body” ultrasound scan are used to differentiate 
between ALS and other diseases. With a negative likelihood ratio of 0.04 (chapter 3.3), 
there is a very low probability that patients with a negative test do have ALS. Therefore, 
in those patients further work-up should be focused on ALS mimics. In patients with a 
positive test, a second step is added to increase the level of diagnostic certainty. 
This second step is based on the number of regions with ultrasonographic lower MN 
involvement, with three or more affected regions indicating a positive test. With a 
specificity of 94% (chapter 3.3), the probability of a false positive test is low. Complete 
EMG examination in patients with a positive step 2 would be redundant. Since the 
ultrasound criteria for lower MN involvement do not contain an equivalent for chronic 
denervation, it is advisable to perform EMG in at least two symptomatic muscles. 
Obviously, additional test should be performed whenever necessary to exclude mimics.
In the remaining patients (positive step 1 and negative step 2), the ultrasound examination 
gives insufficient support to confirm or rule out the diagnosis ALS. Those patients 
deserve a regular work-up for ALS including full EMG examination.  
The accuracy of this flow chart has to be evaluated in an additional study. With improved 
knowledge of ultrasound characteristics of ALS-mimics, the extent of the EMG examination 
might be further limited in the future. Ultrasonography can then be used to confirm the 
diagnosis and detect subclinical regional involvement, while the use of needle EMG can 
be restricted to the exclusion of mimics. 
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FIGURE 2
Implementation of muscle ultrasound in the diagnostic work-up for ALS. In practice, step 1 and 2 are 
derived from the same ultrasound study. LMN; lower motor neuron.
Symptoms and signs suspect 
for ALS
Ultrasound step 1: total body
Positive test
Echo intensity ≥ 1.5 
in ≥ 2 muscles and 
fasciculations in ≥ 4 
muscles
Positive Negative
Ultrasound step 2:  
regional LMN involvement
Positive region
-  Bulbar and thoracic 
region: fasciculations 
in 1 muscle 
-  Cervical and  
lumbosacral region: 
fasciculations in  
2 muscles
LMN involvement 
≥ 3 regions
LMN involvement 
< 3 regions
EMG study of 2 
muscles to confirm 
neurogenic origin
Additional tests to 
exclude ALS mimics, 
when necessary
Regular needle EMG 
and nerve conduction 
studies
Additional tests to 
exclude ALS mimics, 
when necessary
Additional tests, 
including nerve 
conductions studies 
and needle EMG, 
focused on diagnosis 
of ALS-mimics
CONCLUSION
Quantitative muscle ultrasonography is a practical, non-invasive tool to study muscles of 
healthy subjects and of patients with a neuromuscular disease. It is a new tool in the field 
of ALS. Diminished muscle thickness, increased echo intensity and fasciculations can 
be found in an early stage of ALS and even in muscles with preserved strength. Based 
on these findings quantitative muscle ultrasonography can be used in the diagnostic 
work-up of ALS.
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INLEIDING
Amyotrofische laterale sclerose
Amyotrofische laterale sclerose (ALS) is een dodelijke neuromusculaire ziekte (zenuw-
spierziekte) die behoort tot de zogenaamde motor neuron aandoeningen. Bij deze 
aandoeningen sterven de zenuwcellen die betrokken zijn bij de aansturing van spieren. 
Kenmerkende verschijnselen die patiënten met ALS ervaren zijn het dunner en minder 
krachtig worden van de spieren en een verminderde vaardigheid van de spieren 
(spasticiteit). Bovendien valt het patiënten op dat spieren soms spontaan onder de huid 
bewegen (fasciculaties). Meestal beginnen de verschijnselen bij ALS in één van de lede-
maten, waardoor bijvoorbeeld het optillen van een voet of het opendraaien van een kraan 
moeilijk wordt. In ongeveer 20% beginnen de eerste klachten in de mond en keelspieren, 
waardoor er problemen ontstaan met praten en/of slikken. Uiteindelijk breiden de 
verschijnselen zich geleidelijk in een aantal maanden uit naar andere lichaamsdelen. 
Gemiddeld overlijden patiënten met ALS drie jaar na het ontstaan van de eerste klachten. 
 
Voor het aansturen van een spier zijn zenuwcellen (neuronen) nodig die de hersenen met 
de spieren verbinden. Deze neuronen zijn onder te verdelen in de centraal motorische 
neuronen en de perifeer motorische neuronen (figuur 1). De centraal motorische neuronen 
bevinden zich in de hersenen en lopen door naar de hersenstam of het ruggenmerg waar 
ze overschakelen op het perifeer motorische neuron. Het perifeer motorische neuron 
loopt vervolgens door tot aan de spier.  
FIGURE 1
Schematisch overzicht van het centraal en perifeer motorisch neuron.   
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Typisch voor ALS is dat zowel het centraal als het perifeer motorisch neuronen afsterven. 
Beschadiging van het centraal motorische neuron uit zich vooral als spasticiteit. 
Aantasting van het perifeer motorisch neuron veroorzaakt spierzwakte en afname van de 
spierdikte, oftewel atrofie (figuur 2). Een ander zeer karakteristiek verschijnsel voor ALS 
zijn fasciculaties. In het kader van ALS worden fasciculaties gezien als een teken van 
perifeer motor neuron beschadiging. Deze kleine onderhuidse spierbewegingen komen 
echter ook bij gezonde individuen voor, vrijwel iedereen bemerkt wel eens fasciculaties. 
In gezonden lijdt dit echter niet tot spierzwakte.
FIGURE 2
Atrofie van de spieren van de rechter hand. Vooral de spieren tussen de duim en de wijsvinger en 
tussen de middenhandsbeentjes van de rechter hand zijn dunner.   
Diagnose
De diagnose ALS wordt grotendeels gesteld op basis van de anamnese (datgene wat 
een patiënt vertelt) en het lichamelijk onderzoek. Hierbij wordt gezocht naar tekenen 
van beschadiging van het centraal motorisch neuron (spasticiteit) en perifeer motorisch 
neuron (atrofie, zwakte en fasciculaties). Omdat er geen test is waarmee de diagnose 
met 100% zekerheid gesteld kan worden, wordt de diagnose uitgedrukt in mate van 
waarschijnlijkheid. Een hogere mate van zekerheid wordt verkregen als er tekenen van 
zenuwschade worden gezien in meer lichaams’regio’s‘. Het lichaam wordt hiervoor 
ingedeeld in 4 regio’s: bulbair (verschijnselen van mond en keel), cervicaal (verschijnselen 
van met name de armen), thoracaal (verschijnselen van de spieren van de romp en buik) 
en lumbosacraal (verschijnselen van de benen). 
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Een belangrijke hulponderzoek bij het opsporen van tekenen van beschadiging van het 
perifeer motorisch neuron is electromyografie (EMG). Ten gevolge van afsterven van het 
perifeer motorisch neuron verliezen spiervezels het contact met zenuwvezels, dit wordt 
‘spiervezeldenervatie’ genoemd. Bij het EMG wordt met een naald in de spier geprikt 
waardoor onder andere spiervezeldenervatie opgespoord kan worden. Bij ALS wordt 
het EMG vooral gebruikt om spiervezeldenervatie op te sporen in spieren die bij het 
lichamelijk onderzoek niet aangedaan lijken te zijn, om de diagnose met meer zekerheid 
te kunnen stellen. 
FIGURE 3
Het echografische verschil tussen gezonde spieren en spieren aangedaan door een neuromusculaire 
aandoening. Links de scan en de schematische weergave van de biceps van een gezonde vrijwilliger, 
rechts van een patiënt met een neuromusculaire aandoening. De biceps van de patiënt met een neuro-
musculaire aandoening is witter (vertoont een hogere echo intensiteit ) en is dunner.   
Spierechografie
Echografie is een techniek waarmee met behulp van geluidsgolven organen in beeld 
gebracht kunnen worden, waaronder spieren. In 1980 werd voor het eerst het gebruik 
van echografie in neuromusculaire aandoeningen beschreven. Spieren die zijn aan-
gedaan door een neuromusculaire aandoening bleken er dunner en witter uit te zien dan 
gezonde spieren (figuur 3). Aanvankelijk werd op het oog beoordeeld of een spier er 
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afwijkend uitzag. Tegenwoordig worden zowel de spierdikte als de witheid van de spier, 
oftewel de echo intensiteit, heel precies gemeten met behulp van de computer. Deze zo-
genaamde kwantitatieve analyse van de echo intensiteit is objectiever en blijkt ook kleine 
veranderingen in de spier te kunnen vinden die gemist kunnen worden bij puur visuele 
beoordeling. Voor kwantitatieve analyse is het natuurlijk van belang om normaalwaarden 
te hebben van gezonde proefpersonen, zodat het duidelijk is wanneer waardes 
afwijkend zijn. 
DOELSTELLING VAN DIT PROEFSCHRIFT
Het overkoepelende doel van dit proefschrift is het onderzoeken van de waarde van kwanti-
tatieve spierechografie bij ALS. We zijn begonnen met het vaststellen van normaalwaardes 
voor spierdikte, echo intensiteit en fasciculaties. Daarna hebben we specifieke spierecho-
grafie veranderingen bij ALS bestudeerd. Tenslotte hebben we de waarde van echografie 
bepaald bij het stellen van de diagnose van ALS, en het voorspellen van het ziektebeloop. 
RESULTATEN  
SPIERECHOGRAFIE BIJ GEZONDE VOLWASSENEN
In het eerste deel van dit proefschrift hebben we het effect van geslacht en leeftijd op 
spieren onderzocht en hebben we normaalwaarden voor spierdikte en echointenisiteit 
verkregen. Daarnaast werd naar het voorkomen van fasciculaties bij gezonde proef-
personen gekeken. 
Spierdikte
In hoofdstuk 2.1 en 2.2 beschrijven we normaalwaarden voor spierdikte en laten we 
de invloed zien van leeftijd op spierdikte. Hiervoor werden echoscans gemaakt van de 
m. biceps (buigspier van de elleboog) en de m. quadriceps (strekspier van de knie) bij 
194 gezonde vrijwilligers met een leeftijd variërend van 2 maanden tot 90 jaar (hoofd-
stuk 2.1). Bij 95 van de volwassen vrijwilligers werd ook de m. sternocleidomastoideus 
(een halsspier), de onderarmsflexoren (buigspieren van de vingers en pols) en de 
m. tibialis anterior (voetheffer) gemeten (hoofdstuk 2.2). Leeftijd bleek een sterke invloed te 
hebben op de spierdikte: tot een leeftijd van ongeveer 20 jaar nam de spierdikte het 
sterkst toe, daarna was er een geringere toename te zien waarbij de maximale spierdikte 
werd bereikt tussen de 30-40 jaar, daarna nam de spierdikte af. De mate van spierdikte 
afname was verschillend voor mannen en vrouwen en afhankelijk van de onderzochte 
spier. Hierbij vertoonde de dikste spieren de sterkste afname. Het grootste verval werd 
gezien in de quadriceps van mannen.
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Spierdikte is afhankelijk van leeftijd en geslacht.
Echo intensiteit
In hoofdstuk 2.2 presenteren we normaalwaarden voor echo intensiteit voor 
5 verschillende spiergroepen. We maakten scans van de m. sternocleidomastoideus, 
m. biceps, onderarmsflexoren, m. quadriceps en m. tibialis anterior beiderzijds in 
95 gezonde vrijwilligers van 17-90 jaar. Echo intensiteit was verschillend voor de 
verschillende spieren, voor mannen en vrouwen en vertoonde een relatie met de leeftijd. 
Daarnaast werden er links-rechts verschillen gevonden in een aantal spiergroepen. Echo 
intensiteit nam toe met de leeftijd, waarbij er vooral vanaf 60 jaar werd er een sterke 
toename gezien werd. Deze leeftijdsgerelateerde toename in echo intensiteit was 
geslachts- en spierspecifiek. 
Echo intensiteit is leeftijd, geslacht en spierspecifiek. 
Fasciculaties
In hoofdstuk 2.3 bestuderen we het vóórkomen van fasciculaties in 58 gezonde 
vrijwilligers. Wanneer er gedurende 10 seconden per spier met echo werd gekeken, 
vertoonde 43% van de gezonde vrijwilligers fasciculaties in één of meerdere spieren. 
De meeste fasciculaties werden gevonden in de kleine voetspieren. Slechts in drie proef-
personen werden er fasciculaties gezien in spieren boven de knie. De proefpersonen met 
fasciculaties waren gemiddeld ouder dan diegene zonder fasciculaties.
Een idee is dat fasciculaties uitgelokt kunnen worden door het drinken van veel koffie 
of (intensief) sporten, daarom hebben we deze factoren speciaal bestudeerd. Cafeïne 
en normale fysieke inspanning bleken geen effect te hebben op het voorkomen van 
fasciculaties. In tien vrijwilligers hebben we het effect van intensief sporten beoordeeld, 
door ze een half uur voor en na het sporten te meten. Na het intensief sporten werd er 
een tijdelijke toename van de fasciculaties gevonden. 
Fasciculaties kunnen gevonden worden in een groot deel van gezonde vrijwilligers, 
met name in voetspieren. Fasciculaties komen vooral voor bij hogere leeftijd en na 
forse inspanning. Er lijkt geen relatie te bestaan tussen cafeïnegebruik of reguliere 
inspanning en fasciculaties. 
SPIERECHOGRAFIE BIJ ALS
In dit deel van het proefschrift beschrijven we het belang van spierechografie bij ALS voor 
onder meer het stellen van de diagnose, het vastleggen van het beloop en het voorspellen 
van de prognose.  
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Spierecho bevindingen bij ALS
In hoofdstuk 3.1 onderzoeken we of met kwantitatieve spierechografie al in een vroeg 
stadium van ALS spierveranderingen gevonden konden worden. In 48 ALS patiënten 
werden scans gemaakt van diverse hals-, arm- en beenspieren. Vijfentwintig patiënten 
werden ook gescreend op het voorkomen van fasciculaties. De echo intensiteit bleek 
meer afwijkend dan de spierdikte: de gemiddelde echo intensiteit was verhoogd voor 
alle spieren, een verminderde spierdikte werd gevonden in de m. biceps, de onder-
armsflexoren en m. quadriceps beiderzijds. Alle patiënten op één na, vertoonden 
fasciculaties in meerdere spieren. Het gemiddeld aantal spieren met fasciculaties was 
6,5 van de tien gemeten spieren. In hoofdstuk 3.4 laten we zien dat spierdikte en 
echo intensiteit samenhang vertonen met kracht; zwakke spieren hadden een hogere 
echo intensiteit en waren dunner dan krachtigere spieren. Echter, zelfs in spieren met 
nog intacte kracht konden al spierecho veranderingen gevonden worden: in ongeveer 
30% van deze spieren werd een verminderde spierdikte of verhoogde echo intensiteit 
gezien en in 63% fasciculaties. 
Echografie laat een verhoogde echo intensiteit, afgenomen spierdikte en fasciculaties 
zien bij ALS, zelfs in spieren met nog intacte spierkracht.
Correlatie met histopathologie
Om beter te begrijpen wat de oorzaak is van de verhoogde echo intensiteit, vergelijken we 
in hoofdstuk 3.2 de echo bevindingen met microscopisch onderzoek van spierweefsel 
dat na het overlijden van een ALS patiënte werd verkregen. Spierecho scans van negen 
spieren werden gemaakt tijdens leven en daarna vergeleken met spierweefsel dat 
uitgenomen was (na overlijden) op dezelfde plaats. Echo intensiteit vertoonde een sterke 
samenhang met de hoeveelheid bindweefsel in de spier, maar niet met de hoeveelheid 
vetweefsel in de spier. 
Echo intensiteit is sterk gecorreleerd met de hoeveelheid bindweefsel in de spier.
Diagnose
In hoofdstuk 3.3 onderzochten we of spierechografie gebruikt kan worden om onder-
scheid te maken tussen ALS en ziekten die (soms sterk) op ALS kunnen lijken, de 
zogenaamde “ALS-mimics”. Vijfennegentig patiënten, met klachten en verschijnselen die 
zouden kunnen wijzen op ALS, maar nog zonder een uiteindelijke diagnose, werden 
in het onderzoek betrokken. Gedurende een dagopname kregen deze patiënten niet 
alleen het ‘standaard’ ALS onderzoek, maar ook een uitgebreid spierecho onderzoek. 
De neuroloog stelde de uiteindelijk diagnose (ALS of ALS-mimic) zonder informatie over 
de uitslag van de spierecho. Pas later werd gekeken in hoeverre de diagnose ook op 
basis van de uitslag van het spierecho onderzoek gesteld had kunnen worden. Spier-
echografie bleek goed te kunnen differentiëren tussen ALS en ALS-mimics. Daarnaast 
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bleek echografie een gevoelige methode om regio’s te detecteren met perifeer motor 
neuron betrokkenheid. In de 27 patiënten met ALS werden met echografie 15 aangedane 
regio’s gevonden die met klinisch onderzoek of EMG ongestoord waren. 
Spierechografie kan onderscheid maken tussen ALS en ALS-mimics met hoge 
sensitiviteit en specificiteit. Het is ook een gevoelige methode om regionaal perifeer 
motor neuron betrokkenheid aan te tonen.
Ziekteprogressie
In hoofdstuk 3.4 hebben we ons gericht op spierveranderingen tijdens het ziektebeloop 
van ALS. Voor dit onderzoek werden 31 ALS patiënten gedurende een half jaar elke zes 
weken onderzocht. Tijdens de onderzoeksmomenten werden spierecho’s gemaakt van 
zes verschillende spiergroepen, werd de kracht getest van verschillende spieren en een 
speciaal voor ALS ontwikkelde vragenlijst afgenomen die de mate van beperking meet 
(de gereviseerde ALS functional rating scale; ALSFRS-r). Er bleken grote verschillen 
tussen patiënten in het beloop van echo intensiteit, spierdikte en fasciculaties. Opvallend 
was dat een aantal patiënten zelfs een toename in spierdikte of een afname van de 
echo intensiteit liet zien gedurende het ziektebeloop. Mogelijk komt dit door training, 
bijvoorbeeld door fysiotherapie. We vonden geen samenhang tussen de mate van 
verandering in spierechoparameters en kracht of de ALSFRS-r. 
Spierechografie is niet geschikt om het ziektebeloop van ALS vast te leggen.
Overleving
In hoofdstuk 3.5 hebben we de voorspellende waarde van spierechografie in 31 patiënten 
met ALS onderzocht en vergeleken met veel gebruikte methodes om de overlevings-
duur te voorspellen zoals de ALSFRS-r, ziekteduur, leeftijd en spierkracht. Iedere patiënt 
werd één keer onderzocht. Naast de reguliere waarden van spierdikte, echointensiteit en 
fasciculaties, werden ook de zogenaamde “preslope” waardes berekend. Deze preslope 
waarde is de geschatte mate van verandering van een bepaalde uitkomstmaat vooràf-
gaand aan de eerste meting. De echo intensiteit preslope, ziekteduur, de spierkracht 
preslope en de ALSFRS-r preslope vertoonden allen een samenhang met overleving. 
Patiënten met een lagere preslope echo intensiteit (dus een minder snelle toename 
van de echo intensiteit) bleken een gemiddelde levensduur van bijna 60 maanden te 
hebben na het ontstaan van de eerste ziekteverschijnselen. Bij patiënten met een hogere 
echo intensiteit preslope was dit iets meer dan 40 maanden. De combinatie van de echo 
intensiteit preslope en ALSFRS-r preslope bleek het beste de overlevingsduur te kunnen 
voorspellen. Het aantal onderzochte patiënten in deze studie was relatief laag, daarom is 
er een grotere studie nodig om deze resultaten te bevestigen.
 
Met één spierecho onderzoek kan de overlevingsduur bij ALS voorspeld worden.
 
CHAPTER 6
Appendices
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